<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03737110</url>
  </required_header>
  <id_info>
    <org_study_id>KPL-914-C002</org_study_id>
    <secondary_id>2018-002719-87</secondary_id>
    <nct_id>NCT03737110</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis</brief_title>
  <acronym>RHAPSODY</acronym>
  <official_title>Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study With Open-label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kiniksa Pharmaceuticals (UK), Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kiniksa Pharmaceuticals, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to assess the efficacy of rilonacept treatment in&#xD;
      participants with recurrent pericarditis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the single-blind run-in (RI) period, rilonacept 320 mg (or 4.4 mg/kg in pediatric&#xD;
      participants ≥12 and &lt;18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in&#xD;
      pediatric participants ≥12 and &lt;18 years old) injections once weekly.&#xD;
&#xD;
      During the Randomized-Withdrawal (RW) period, eligible participants are randomized 1:1 to&#xD;
      double-blinded administration of study drug:&#xD;
&#xD;
        -  Rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) SC&#xD;
           injections once weekly&#xD;
&#xD;
        -  Matching placebo SC injections once weekly.&#xD;
&#xD;
      Participants with pericarditis recurrence who meet the protocol criteria for bailout&#xD;
      rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point numerical rating&#xD;
      scale (NRS) and have 1 C-reactive protein (CRP) value ≥ 1 mg/dL [either on the same day or&#xD;
      separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160&#xD;
      mg rilonacept [or 4.4 mg/kg for pediatric subjects]) irrespective of randomized treatment&#xD;
      assignment and as soon as at least 5 days have passed since the last study drug injection.&#xD;
&#xD;
      Upon completion of the RW period (i.e., when the prespecified number of primary efficacy&#xD;
      endpoints [clinical events committee-confirmed pericarditis recurrence] events have&#xD;
      occurred), all participants who did not discontinue study drug have an option to continue&#xD;
      treatment with open-label rilonacept in the Long-Term Extension (LTE) or to withdraw from the&#xD;
      study. Participants still in the RI period at the time that the RW period has ended and the&#xD;
      LTE is opened will have the option to enter the LTE directly when they have completed the RI&#xD;
      period and have met the definition of clinical response or to withdraw from the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 7, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Actual">May 29, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Pericarditis Recurrence in the RW Period</measure>
    <time_frame>RW Period (mean 24.8 weeks)</time_frame>
    <description>Time to pericarditis recurrence (from randomization to 1st recurrence). Kaplan-Meier. Clinical Events Committee (CEC)-confirmed recurrences used for primary analysis. Recurrence defined as recurrence typical pericarditis pain with supportive objective evidence. CEC-adjudicated recurrences defined as:1) Re-appearance/worsening pericarditis pain (1 NRS ≥ 4) AND elevated CRP (≥1.0 mg/dL) on same day/separated by ≤ 7 days OR 2) Re-appearance/worsening pericarditis pain (1 NRS ≥ 4) AND abnormal CRP (&gt; 0.5 mg/dL) on same day/separated by ≤ 7 days AND 1 supportive evidence OR 3) Re-appearance/worsening pericarditis pain (no NRS ≥ 4) AND elevated CRP (≥ 1.0 mg/dL) not attributable to other causes AND 1 supportive evidence. Supportive evidence: White blood cell count &gt; upper limit normal, fever &gt; 38C, pericardial rub, electrocardiogram changes consistent with pericarditis, new/worsening pericardial effusion (echocardiogram), new/worsening pericardial inflammation (magnetic resonance imaging).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Secondary Efficacy Endpoint: Percentage of Participants Who Maintained Clinical Response at Week 16 of the RW Period</measure>
    <time_frame>RW Period Week 16</time_frame>
    <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Clinical response was defined as a weekly average of daily pericarditis pain on the NRS ≤ 2.0 and C-reactive protein (CRP) level ≤ 0.5 mg/dL, and on monotherapy of randomized study drug at Week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Secondary Efficacy Endpoint: Percentage of Days With No or Minimal Pericarditis Pain at Week 16 of the RW Period</measure>
    <time_frame>RW Period Week 16</time_frame>
    <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. No or minimal pain was defined as non-missing NRS ≤ 2.&#xD;
The percentage of days with no or minimal pericarditis pain in the first 16 weeks was calculated for each participant using 16×7 as the denominator. Missing values in pain diary were counted as 0 day with no or minimal pain. Days of using oral rescue therapy or corticosteroid count as 0 day with no or minimal pain. If bailout rilonacept was used, each administration (loading dose or not) was counted as 7 days without qualifying no or minimal pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Secondary Efficacy Endpoint: Percentage of Participants With Absent or Minimal Pericarditis Symptoms Based on the Patient Global Impression of Pericarditis Severity (PGIPS) at Week 16 of the RW Period</measure>
    <time_frame>RW Period Week 16</time_frame>
    <description>Percentage of participants with no or minimal pericarditis symptoms at Week 16, based on the PGIPS, a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered using a 7-point rating scale ranging from absent (0=no recurrent pericarditis symptoms) to very severe (6=recurrent pericarditis symptoms that cannot be ignored and markedly limits daily activities).&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Maintained Clinical Response at Week 24 of the RW Period</measure>
    <time_frame>RW Period Week 24</time_frame>
    <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Clinical response was defined as a weekly average of daily pericarditis pain on the NRS ≤ 2.0 and C-reactive protein (CRP) level ≤ 0.5 mg/dL, and on monotherapy of randomized study drug at Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Maintained Clinical Response at Week 8 of the RW Period</measure>
    <time_frame>RW Period Week 8</time_frame>
    <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Clinical response was defined as a weekly average of daily pericarditis pain on the NRS ≤ 2.0 and C-reactive protein (CRP) level ≤ 0.5 mg/dL, and on monotherapy of randomized study drug at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With No or Minimal Pericarditis Pain at Week 24 of the RW Period</measure>
    <time_frame>RW Period Week 24</time_frame>
    <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. No or minimal pain was defined as non-missing NRS ≤ 2.&#xD;
The percentage of days with no or minimal pericarditis pain in the first 24 weeks was calculated for each participant using 24×7 as the denominator. Missing values in pain diary were counted as 0 day with no or minimal pain. Days of using oral rescue therapy or corticosteroid count as 0 day with no or minimal pain. If bailout rilonacept was used, each administration (loading dose or not) was counted as 7 days without qualifying no or minimal pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With No or Minimal Pericarditis Pain at Week 8 of the RW Period</measure>
    <time_frame>RW Period Week 8</time_frame>
    <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. No or minimal pain was defined as non-missing NRS ≤ 2.&#xD;
The percentage of days with no or minimal pericarditis pain in the first 24 weeks was calculated for each participant using 8×7 as the denominator. Missing values in pain diary were counted as 0 day with no or minimal pain. Days of using oral rescue therapy or corticosteroid count as 0 day with no or minimal pain. If bailout rilonacept was used, each administration (loading dose or not) was counted as 7 days without qualifying no or minimal pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Absent or Minimal Pericarditis Symptoms at Week 24 of the RW Period Based on the PGIPS</measure>
    <time_frame>RW Period Week 24</time_frame>
    <description>Percentage of participants with no or minimal pericarditis symptoms at Week 24, based on the PGIPS, a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered using a 7-point rating scale ranging from absent (0=no recurrent pericarditis symptoms) to very severe (6=recurrent pericarditis symptoms cannot be ignored and markedly limits daily activities).&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Absent or Minimal Pericarditis Symptoms at Week 8 of the RW Period Based on the PGIPS</measure>
    <time_frame>RW Period Week 8</time_frame>
    <description>Percentage of participants with no or minimal pericarditis symptoms at Week 16, based on the Patient Global Impression of Pericarditis Severity (PGI-PS). The PGI-PS is a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered, using a 7-point rating scale ranging from absent (no recurrent pericarditis symptoms) to very severe (recurrent pericarditis symptoms cannot be ignored).&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Without Pericarditis Recurrence in the First 24 Weeks of the RW Period</measure>
    <time_frame>up to 24 weeks in the RW Period</time_frame>
    <description>Pericarditis recurrence is defined as the recurrence of typical pericarditis pain associated with supportive objective evidence of pericarditis. At any time during the RW period, participants who experienced a suspected recurrence of pericarditis symptoms reported to the study site/clinic for a scheduled or unscheduled visit, during which clinical assessments were performed to gather all the necessary diagnostic data to confirm or rule out the presence of pericarditis recurrence. A pericarditis recurrence event adjudication package was then prepared for adjudication by CEC. Kaplan-Meier estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Pericarditis Pain ≥ 4 on the NRS in the RW Period</measure>
    <time_frame>RW Period (mean 24.8 weeks)</time_frame>
    <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CRP Level ≥ 1 mg/dL in the RW Period</measure>
    <time_frame>RW Period (mean 24.8 weeks)</time_frame>
    <description>Kaplan-Meier estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Pericardial Rub in the RW Period</measure>
    <time_frame>RW Period (mean 24.8 weeks)</time_frame>
    <description>Kaplan-Meier estimate. A pericardial rub (also called a pericardial friction rub) is an audible medical sign used in the diagnosis of pericarditis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Widespread ST-segment Elevation or PR-segment Depression on Electrocardiogram (ECG) in the RW Period</measure>
    <time_frame>RW Period (mean 24.8 weeks)</time_frame>
    <description>Kaplan-Meier estimate. ST-segment elevation and PR-segment depression are ECG changes in the evolution of acute pericarditis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to New or Worsening Pericardial Effusion on Echocardiography (ECHO) in the RW Period</measure>
    <time_frame>RW Period (mean 24.8 weeks)</time_frame>
    <description>Pericardial effusion based on ECHO was evaluated by the central laboratory during the RW period. Kaplan-Meier estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in ECHO Pericardial Effusion Size Categories at RW Period Baseline, RW Week 24 and Worst Post-baseline in the RW Period</measure>
    <time_frame>RW Period Baseline, RW Period Week 24, RW Period (mean 24.8 weeks)</time_frame>
    <description>Pericardial effusion based on ECHO was evaluated by the central laboratory during the RW period. &quot;None or trivial/physiologic&quot; is considered to be normal. The &quot;RW Worst Post-baseline&quot; category denotes the largest size of pericardial effusion category in which a participant was reported at any time during the RW period (post-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From RW Period Baseline Over Time in CRP Levels in RW Period</measure>
    <time_frame>RW Period Baseline, RW Period Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, 56</time_frame>
    <description>Estimated from ANCOVA models including treatment arm as fix effect, baseline value, baseline value by treatment interaction, randomization strata as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From RW Period Baseline Over Time in Weekly Average of Pericarditis Pain in the RW Period</measure>
    <time_frame>RW Period Baseline, RW Period Weeks 1-50, 54</time_frame>
    <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Estimated from ANCOVA models including treatment arm as fix effect, baseline value, baseline value by treatment interaction, randomization strata as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Absent or Minimal Pericarditis Symptoms Over Time After RW Period Week 24 Based on the PGIPS</measure>
    <time_frame>RW Period Weeks 32, 40, 48, 56</time_frame>
    <description>The PGIPS, a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered using a 7-point rating scale ranging from absent (0=no recurrent pericarditis symptoms) to very severe (6=recurrent pericarditis symptoms cannot be ignored and markedly limits daily activities).&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Absent or Minimal Pericarditis Activity Over Time in the RW Period Based on the Physician Global Assessment of Pericarditis Activity (PGA-PA)</measure>
    <time_frame>RW Period Baseline, RW Period Weeks 8, 16, 24, 32, 40, 48, 56</time_frame>
    <description>The PGA-PA is a single-item, clinician-reported outcome measure that Investigators use to rate their impression of the patient's overall pericarditis disease activity at the time the assessment is completed, using a rating scale ranging from absent to very severe. The Investigator selected the box that best described a participant's pericarditis activity at the time of occurrence of the assessment: Absent, Minimal, Mild, Moderate, Moderately Severe, Severe, Very Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From RW Period Baseline in Short Form-36 (SF-36) Physical and Mental Component Scores at RW Period Week 24</measure>
    <time_frame>RW Period Baseline, RW Period Week 24</time_frame>
    <description>The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the physical component summary (PCS) score of the SF-36. Items 5-8 primarily contribute to the mental component summary (MCS) score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best) with higher scores indicating better health. Increases from baseline indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From RW Baseline in SF-36 Individual Scores at RW Period Week 24</measure>
    <time_frame>RW Period Baseline, RW Period Week 24</time_frame>
    <description>The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scores on each item are summed and averaged (range: 0=worst to 100=best) with higher scores indicating better health. Increases from baseline indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From RW Period Baseline in the Short Form Health Survey-6 Domains (SF-6D) Utility Index Score at RW Period Week 24</measure>
    <time_frame>RW Period Baseline, RW Period Week 24</time_frame>
    <description>The SF-6D is calculated based on responses to 11 items on the SF-36, that correspond to 6 domains: physical functioning, role participation (combined role-physical and role-emotional), social functioning, bodily pain, mental health, and vitality. Individual respondents can be classified on any of 4 to 6 levels of functioning or limitations for each of 6 domains, thus allowing a respondent to be classified into any of 18,000 possible unique health states. Using a standard gamble technique, each of these health states were mapped onto the SF-6D index score, which ranges from 0.00 (worst possible health state/death) to 1.00 (best possible health state/perfect health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From RW Period Baseline in 5-level EuroQoL-5 Dimensions (EQ-5D-5L) Individual Scores and Index Value to RW Period Week 24</measure>
    <time_frame>RW Period Baseline, RW Period Week 24</time_frame>
    <description>The EQ-5D-5L is a self-reported health status questionnaire that consists of 6 questions used to calculate a health utility score for use in health economic analysis. There are 2 components to the EQ-5D-5L: a 5-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Individual and index scores range from 0 to 1, with low scores representing a higher level of dysfunction. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From RW Period Baseline in Insomnia Severity Index (ISI) Total Score at RW Period Week 24</measure>
    <time_frame>RW Period Baseline, RW Period Week 24</time_frame>
    <description>Participant's sleep quality was assessed with the ISI survey questionnaire. The ISI is a 7-item survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. Scores are summed for a total score, which ranges from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia.&#xD;
Clinical interpretation of the total score is as follows:&#xD;
0 to 7 = no clinically significant insomnia; 8 to 14 = subthreshold insomnia; 15 to 21 = clinical insomnia (moderate severity); 22 to 28 = clinical insomnia (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ISI Categories From RW Period Baseline to RW Period Week 24</measure>
    <time_frame>RW Period Baseline (BL), RW Period Week (Wk) 24</time_frame>
    <description>Participant's sleep quality was assessed with the ISI survey questionnaire. The ISI is a 7-item survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. Scores are summed for a total score, which ranges from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia.&#xD;
Clinical interpretation of the total score is as follows:&#xD;
0 to 7 = no clinically significant insomnia; 8 to 14 = subthreshold insomnia; 15 to 21 = clinical insomnia (moderate severity); 22 to 28 = clinical insomnia (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Using Oral Rescue Therapy (ORT), Corticosteroid, or Bailout Rilonacept for Pericarditis Every 4 Weeks Cumulatively in the RW Period</measure>
    <time_frame>RW Period (mean 24.8 weeks)</time_frame>
    <description>ORT included analgesics, NSAIDs, and/or colchicine. ORT use while waiting for at least 5 days since previous administration of study drug before receiving bailout, or within 5 days before the assessment of pericarditis recurrence, was excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Using ORT for Pericarditis in the First 24 Weeks of RW Period</measure>
    <time_frame>RW Period (up to Week 24)</time_frame>
    <description>ORT included analgesics, NSAIDs, and/or colchicine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pericardial Delayed Hyperenhancement, Myocardial Delayed Hyperenhancement or Pericardial Effusion on Magnetic Resonance Imaging (MRI) at RW Week 24</measure>
    <time_frame>RW Period Week 24</time_frame>
    <description>MRI assessments were performed in a subgroup of participants (MRI substudy) to assess the percentage of participants with:&#xD;
Pericardial delayed hyperenhancement&#xD;
Myocardial delayed hyperenhancement&#xD;
Pericardial effusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From First Dose to Pain Response in the RI Period</measure>
    <time_frame>RI Period (up to 12 weeks)</time_frame>
    <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Time to pain response was defined as number of days from first dose to the first day a participant's daily pain NRS was ≤ 2 of the 3 days over which the rolling average daily pain NRS was ≤ 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From First Dose to CRP Normalization in the RI Period</measure>
    <time_frame>RI Period (up to 12 weeks)</time_frame>
    <description>Time to CRP normalization, defined as CRP ≤ 0.5 mg/dL, was censored at treatment discontinuation, taking prohibited medication, or Week 12, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From First Dose to Rilonacept Monotherapy in RI Period</measure>
    <time_frame>RI Period (up to 12 weeks)</time_frame>
    <description>Time to rilonacept monotherapy was defined as the number of weeks from first dose to the first day of achieving monotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From First Dose to Treatment Response in RI Period</measure>
    <time_frame>RI Period (up to 12 weeks)</time_frame>
    <description>Time to treatment response is defined as time from first dose to the first day of pain response, and CRP ≤ 0.5 mg/dL within 7 days before or after pain response. Treatment response day will be the first day that the above criterion is met. If pain response occurs before CRP ≤ 0.5 mg/dL, each 3-day rolling average of NRS should be ≤ 2.0 from the day of pain response to the day of CRP ≤ 0.5 mg/dL. The response day will be the day of pain response. If CRP ≤0.5 mg/dL occurs before pain response, the response day will also be the day of pain response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Clinical Response at RI Period Week 12</measure>
    <time_frame>RI Period Week 12</time_frame>
    <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Clinical Response was defined as a weekly average of daily pericarditis pain of ≤ 2.0 on the 11-point NRS and CRP level ≤ 0.5 mg/dL and participants must have been able to stop background SOC pericarditis therapy by Week 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CRP Normalization at RI Period Week 12</measure>
    <time_frame>RI Period Week 12</time_frame>
    <description>CRP normalization was defined as CRP ≤ 0.5 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Over Time in Weekly Average of Pericarditis Pain NRS Score in RI Period</measure>
    <time_frame>RI Period Baseline, RI Period Weeks 1-12</time_frame>
    <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Over Time in CRP Levels in RI Period</measure>
    <time_frame>RI Period Baseline, RI Period Day 4, Weeks 1, 2, 4, 6, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Resolution of Pericarditis-Related ECHO and ECG Abnormalities at Week 12 of the RI Period</measure>
    <time_frame>RI Period Baseline, RI Period Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With No or Minimal Pain in the RI Period While on Treatment</measure>
    <time_frame>RI Period (up to Week 12)</time_frame>
    <description>No or minimal pain is defined as non-missing daily NRS ≤ 2, where participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point NRS, where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With No or Minimal Pericarditis Symptoms Over Time in the RI Period, Based on the PGIPS</measure>
    <time_frame>RI Period Baseline, RI Period Weeks 6 and 12</time_frame>
    <description>The PGIPS, a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered using a 7-point rating scale ranging from absent (0=no recurrent pericarditis symptoms) to very severe (6=recurrent pericarditis symptoms cannot be ignored and markedly limits daily activities).&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With No or Minimal Pericarditis Activity Over Time in the RI Period, Based on the PGA-PA</measure>
    <time_frame>RI Period Baseline, RI Period Weeks 6 and 12</time_frame>
    <description>The PGA-PA is a single-item, clinician-reported outcome measure that Investigators use to rate their impression of the patient's overall pericarditis disease activity at the time the assessment is completed, using a rating scale ranging from absent to very severe. The Investigator selected the box that best described a participant's pericarditis activity at the time of occurrence of the assessment: Absent, Minimal, Mild, Moderate, Moderately Severe, Severe, Very Severe.&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From RI Period Baseline in the SF-36 Domain Scores and Physical and Mental Scores to RI Period Week 12</measure>
    <time_frame>RI Period Baseline, RI Period Week 12</time_frame>
    <description>The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scores on each item are summed and averaged (range: 0=worst to 100=best) with higher scores indicating better health. Increases from baseline indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From RI Period Baseline in SF-6D Scores at RI Period Week 12</measure>
    <time_frame>RI Period Baseline, RI Period Week 12</time_frame>
    <description>The SF-6D is calculated based on responses to 11 items on the SF-36, that correspond to 6 domains: physical functioning, role participation (combined role-physical and role-emotional), social functioning, bodily pain, mental health, and vitality. Individual respondents can be classified on any of 4 to 6 levels of functioning or limitations for each of 6 domains, thus allowing a respondent to be classified into any of 18,000 possible unique health states. Using a standard gamble technique, each of these health states were mapped onto the SF-6D index score, which ranges from 0.00 (worst possible health state/death) to 1.00 (best possible health state/perfect health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From RI Period Baseline in 5-level EuroQoL-5 Dimensions (EQ-5D-5L) Individual Scores and Index Value at RI Period Week 12</measure>
    <time_frame>RI Period Baseline, RI Period Week 12</time_frame>
    <description>The EQ-5D-5L is a self-reported health status questionnaire that consists of 6 questions used to calculate a health utility score for use in health economic analysis. There are 2 components to the EQ-5D-5L: a 5-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Individual and index scores range from 0 to 1, with low scores representing a higher level of dysfunction. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From RI Period Baseline in ISI Total Score at RI Period Week 12</measure>
    <time_frame>RI Period Baseline, RI Period Week 12</time_frame>
    <description>Participant's sleep quality was assessed with the ISI survey questionnaire. The ISI is a 7-item survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. Scores are summed for a total score, which ranges from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia.&#xD;
Clinical interpretation of the total score is as follows:&#xD;
0 to 7 = no clinically significant insomnia; 8 to 14 = subthreshold insomnia; 15 to 21 = clinical insomnia (moderate severity); 22 to 28 = clinical insomnia (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ISI Categories From RI Period Baseline to RI Period Week 12</measure>
    <time_frame>RI Period Baseline (BL), RI Period Week (Wk) 12</time_frame>
    <description>Participant's sleep quality was assessed with the ISI survey questionnaire. The ISI is a 7-item survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. Scores are summed for a total score, which ranges from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia.&#xD;
Clinical interpretation of the total score is as follows:&#xD;
0 to 7 = no clinically significant insomnia; 8 to 14 = subthreshold insomnia; 15 to 21 = clinical insomnia (moderate severity); 22 to 28 = clinical insomnia (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Were Off Background Pericarditis Medication on or Before RI Period Weeks 4, 8, 10, and 12</measure>
    <time_frame>RI Period Baseline, RI Period Weeks 4, 8, 10, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pericarditis Recurrences (Based on Investigators' Judgement) in the Long-Term Extension (LTE) Period</measure>
    <time_frame>LTE Period (up to 24 months)</time_frame>
    <description>Pericarditis recurrence is defined as the recurrence of typical pericarditis pain associated with supportive objective evidence of pericarditis. At any time during the RW period, participants who experienced a suspected recurrence of pericarditis symptoms reported to the study site/clinic for a scheduled or unscheduled visit, during which clinical assessments were performed to gather all the necessary diagnostic data to confirm or rule out the presence of pericarditis recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response at Each CRP Assessment (Weeks 12 and 24) of the LTE Period</measure>
    <time_frame>LTE Period Weeks 12 and 24</time_frame>
    <description>Clinical response is defined as rilonacept monotherapy + CRP ≤ 0.5 mg/dL + NRS ≤ 2. Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point NRS, where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. The pain NRS at the visit when CRP was assessed was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From LTE Baseline Over Time in CRP Levels</measure>
    <time_frame>LTE Baseline, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From LTE Baseline Over Time in Pericarditis Pain NRS</measure>
    <time_frame>LTE Baseline, up to 24 months</time_frame>
    <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point NRS, where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Absent or Minimal Pericarditis Activity In the LTE Period Based on the PGIPS</measure>
    <time_frame>LTE Period (up to 24 months)</time_frame>
    <description>Percentage of participants with no or minimal pericarditis symptoms in the LTE Period, based on the PGIPS, a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered using a 7-point rating scale ranging from absent (0=no recurrent pericarditis symptoms) to very severe (6=recurrent pericarditis symptoms that cannot be ignored and markedly limits daily activities).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Absent or Minimal Pericarditis Activity Over Time in the LTE Period Based on the PGA-PA</measure>
    <time_frame>LTE Period (up to 24 months)</time_frame>
    <description>The PGA-PA is a single-item, clinician-reported outcome measure that Investigators use to rate their impression of the patient's overall pericarditis disease activity at the time the assessment is completed, using a rating scale ranging from absent to very severe. The Investigator selected the box that best described a participant's pericarditis activity at the time of occurrence of the assessment: Absent, Minimal, Mild, Moderate, Moderately Severe, Severe, Very Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From RI Baseline in the SF-36 Domain Scores and Physical and Mental Scores in the LTE Period</measure>
    <time_frame>LTE Baseline, up to 24 months</time_frame>
    <description>The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scores on each item are summed and averaged (range: 0=worst to 100=best) with higher scores indicating better health. Increases from baseline indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From LTE Baseline in SF-6D Scores in LTE Period</measure>
    <time_frame>LTE Baseline, up to 24 months</time_frame>
    <description>The SF-6D is calculated based on responses to 11 items on the SF-36, that correspond to 6 domains: physical functioning, role participation (combined role-physical and role-emotional), social functioning, bodily pain, mental health, and vitality. Individual respondents can be classified on any of 4 to 6 levels of functioning or limitations for each of six domains, thus allowing a respondent to be classified into any of 18,000 possible unique health states. Using a standard gamble technique, each of these health states were mapped onto the SF-6D index score, which ranges from 0.00 (worst possible health state/death) to 1.00 (best possible health state/perfect health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From LTE Baseline in EQ-5D-5L Individual Scores and Index Value in the LTE Period</measure>
    <time_frame>LTE Baseline, up to 24 months</time_frame>
    <description>The EQ-5D-5L is a self-reported health status questionnaire that consists of 6 questions used to calculate a health utility score for use in health economic analysis. There are 2 components to the EQ-5D-5L: a 5-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Individual and index scores range from 0 to 1, with low scores representing a higher level of dysfunction. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From LTE Baseline in ISI Total Score in the LTE Period</measure>
    <time_frame>LTE Baseline, up to 24 months</time_frame>
    <description>Participant's sleep quality was assessed with the ISI survey questionnaire. The ISI is a 7-item survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. Scores are summed for a total score, which ranges from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia.&#xD;
Clinical interpretation of the total score is as follows:&#xD;
0 to 7 = no clinically significant insomnia; 8 to 14 = subthreshold insomnia; 15 to 21 = clinical insomnia (moderate severity); 22 to 28 = clinical insomnia (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From LTE Baseline in ISI Categories in the LTE Period</measure>
    <time_frame>LTE Baseline, up to 24 months</time_frame>
    <description>Participant's sleep quality was assessed with the ISI survey questionnaire. The ISI is a 7-item survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. Scores are summed for a total score, which ranges from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia.&#xD;
Clinical interpretation of the total score is as follows:&#xD;
0 to 7 = no clinically significant insomnia; 8 to 14 = subthreshold insomnia; 15 to 21 = clinical insomnia (moderate severity); 22 to 28 = clinical insomnia (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Addition of Standard of Care (SOC) Pericarditis Therapy Every 4 Weeks Cumulatively in the LTE Period</measure>
    <time_frame>LTE Period (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From LTE Baseline in Pericardial Signs in ECHO in the LTE Period</measure>
    <time_frame>LTE Baseline, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From LTE Baseline in Pericardial Signs in ECG in LTE Period</measure>
    <time_frame>LTE Baseline, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From LTE Baseline in Pericardial Signs in MRI in the LTE Period</measure>
    <time_frame>LTE Baseline, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Corticosteroid Use Over Time in the LTE Period</measure>
    <time_frame>LTE Period (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pericardial Delayed Hyperenhancement, Myocardial Delayed Hyperenhancement or Pericardial Effusion at LTE Period Week 24</measure>
    <time_frame>LTE Period, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Recurrent Rate</measure>
    <time_frame>RW and LTE Periods</time_frame>
    <description>Annualized recurrent rate was calculated for participants randomized to rilonacept utilizing pooled data in RW and LTE periods.&#xD;
Pericarditis recurrence was defined as the recurrence of typical pericarditis pain associated with supportive objective evidence of pericarditis. At any time during the RW period, participants who experienced a suspected recurrence of pericarditis symptoms reported to the study site/clinic for a scheduled or unscheduled visit, during which clinical assessments were performed to gather all the necessary diagnostic data to confirm or rule out the presence of pericarditis recurrence.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Recurrent Pericarditis</condition>
  <arm_group>
    <arm_group_label>Rilonacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RI period: single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants) SC, followed by 160 mg (or 2.2 mg/kg in pediatric participants) injections once weekly.&#xD;
RW period: eligible participants randomized to double-blinded administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly. Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.&#xD;
LTE period: open-label administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>RI period: single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants) SC, followed by 160 mg (or 2.2 mg/kg in pediatric participants) injections once weekly.&#xD;
RW period: eligible participants randomized to placebo SC injections once weekly. Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.&#xD;
LTE period: open-label administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rilonacept</intervention_name>
    <description>Rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥12 and &lt;18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Rilonacept</arm_group_label>
    <other_name>KPL-914</other_name>
    <other_name>Arcalyst® for Cryopyrin-Associated Periodic Syndromes (CAPS)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo SC injections once weekly</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged 12 or older&#xD;
&#xD;
          2. Has a diagnosis of recurrent pericarditis&#xD;
&#xD;
          3. Must provide Informed Consent&#xD;
&#xD;
          4. Presents with at least the third episode of pericarditis during screening.&#xD;
&#xD;
          5. Has received nonsteroidal anti-inflammatory drugs (NSAIDs) and/or colchicine and/or&#xD;
             corticosteroids (in any combination), if used, at stable dose levels (or at least not&#xD;
             increased) for at least 3 days prior to first study drug administration&#xD;
&#xD;
          6. Female subjects must be postmenopausal, or incapable of pregnancy or permanently&#xD;
             sterile, or if of childbearing potential must agree to use highly-effective method of&#xD;
             contraception.&#xD;
&#xD;
          7. Must be up-to-date with all immunizations, in agreement with current local&#xD;
             immunization guidelines for immunosuppressed subjects, before first study drug&#xD;
             administration.&#xD;
&#xD;
          8. Is able to adequately maintain a daily subject diary according to protocol.&#xD;
&#xD;
          9. Agrees to refrain from making any new, major lifestyle changes that may affect&#xD;
             pericarditis symptoms (e.g., changing exercise pattern) from the time that the&#xD;
             informed consent form (ICF) is signed through the end of the double-blind randomized&#xD;
             withdrawal period.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Has a diagnosis of pericarditis that is secondary to specific prohibited etiologies.&#xD;
&#xD;
          2. Has a history of immunosuppression, including positive human immunodeficiency virus&#xD;
             (HIV) test results.&#xD;
&#xD;
          3. Has a history of myeloproliferative disorder.&#xD;
&#xD;
          4. Has a history of demyelinating disease or symptoms suggestive of multiple sclerosis.&#xD;
&#xD;
          5. Has a history of active or latent tuberculosis (TB) prior to screening&#xD;
&#xD;
          6. Has chest x-ray at screening or within 12 weeks before receiving first administration&#xD;
             of study drug, with evidence of malignancy or abnormality consistent with prior or&#xD;
             active TB infection.&#xD;
&#xD;
          7. Has a history of positive or intermediate results for hepatitis B surface antigen,&#xD;
             hepatitis B core antibody, or hepatitis C virus antibody at screening.&#xD;
&#xD;
          8. Has a history of malignancy of any organ system within the past 5 years before&#xD;
             screening (other than a successfully treated non metastatic cutaneous squamous cell&#xD;
             carcinoma or basal cell carcinoma and/or localized carcinoma in situ of the cervix).&#xD;
&#xD;
          9. Has a known or suspected current active infection or a history of chronic or recurrent&#xD;
             infectious disease, including, but not limited to, chronic renal infection, chronic&#xD;
             chest infection, sinusitis, recurrent urinary tract infection, or an open, draining&#xD;
             infected skin wound.&#xD;
&#xD;
         10. Has had an organ transplant.&#xD;
&#xD;
         11. In the Investigator's opinion, has a history of alcoholism or drug/chemical abuse&#xD;
             within 2 years before screening.&#xD;
&#xD;
         12. Has a known hypersensitivity to rilonacept or to any of its excipients.&#xD;
&#xD;
         13. Has received an investigational drug during the 30 days before screening or is&#xD;
             planning to receive an investigational drug (other than that administered during this&#xD;
             study) or use an investigational device at any time during the study.&#xD;
&#xD;
         14. In the Investigator's opinion, has any other medical condition that could adversely&#xD;
             affect the subject's participation or interfere with study evaluations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Operations Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Kiniksa Pharmaceuticals (UK), Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheumatology of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Loretto Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60644</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - PPDS</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Consultants of Philadelphia</name>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <zip>19067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GenesisCare - Cardiology Research</name>
      <address>
        <city>Doncaster East</city>
        <state>Victoria</state>
        <zip>3109</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galilee Medical Center</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center at Tel-Hashomer</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Fatebenefratelli Sacco - Ospedale Fatebenefratelli e Oftalmico</name>
      <address>
        <city>Milan</city>
        <state>Lombardy</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Turin</city>
        <state>Piedmont</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, Insalaco A, LeWinter M, Lewis BS, Lin D, Luis SA, Nicholls SJ, Pano A, Wheeler A, Paolini JF; RHAPSODY Investigators. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. N Engl J Med. 2021 Jan 7;384(1):31-41. doi: 10.1056/NEJMoa2027892. Epub 2020 Nov 16.</citation>
    <PMID>33200890</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <results_first_submitted>May 25, 2021</results_first_submitted>
  <results_first_submitted_qc>June 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2021</results_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pericarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rilonacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 10, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03737110/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03737110/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Data presented are from the primary analysis (data cutoff date May 29, 2020).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Run-in Period</title>
          <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.&#xD;
Participants still in the Run-in Period at the time that the Randomized Withdrawal Period has ended (ie, when the prespecified number of primary efficacy endpoint events have occurred) and the Long-Term Extension (LTE) Period is opened will have the option to enter the LTE directly when they have completed the RI period and have met the definition of clinical response or to withdraw from the study.</description>
        </group>
        <group group_id="P2">
          <title>Randomized Withdrawal Period: Rilonacept</title>
          <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point numerical rating scale (NRS) and have 1 C-reactive protein (CRP) value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.&#xD;
Upon completion of the RW period (ie, when the prespecified number of primary efficacy endpoint events has occurred), all participants who did not discontinue study drug have an option to continue treatment with open-label rilonacept in the LTE period or to withdraw from the study.</description>
        </group>
        <group group_id="P3">
          <title>Randomized Withdrawal Period: Placebo</title>
          <description>Double-blind placebo SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.&#xD;
Upon completion of the RW period (ie, when the prespecified number of primary efficacy endpoint events has occurred), all participants who did not discontinue study drug have an option to continue treatment with open-label rilonacept in the LTE period or to withdraw from the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Run-in (RI) Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Continue to RW Period</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Continue Directly to LTE Period</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Meet Clinical Response Criteria</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Randomized Withdrawal (RW) Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Completed, Not Continuing into LTE</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-Term Extension (LTE) Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15">Participants who entered the LTE directly from RI after protocol-specified 22 adjudicated pericarditis recurrence events had accrued.</participants>
                <participants group_id="P2" count="29">1 participant withdrew consent prior to entering LTE.</participants>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants entering the double-blind Randomized Withdrawal Treatment Period.</population>
      <group_list>
        <group group_id="B1">
          <title>Randomized Withdrawal Period: Rilonacept</title>
          <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
        </group>
        <group group_id="B2">
          <title>Randomized Withdrawal Period: Placebo</title>
          <description>Double-blind placebo SC injections once weekly.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.0" spread="15.70"/>
                    <measurement group_id="B2" value="44.8" spread="14.47"/>
                    <measurement group_id="B3" value="46.4" spread="15.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>12 to 17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 to 78 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, Not Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Pericarditis Recurrence in the RW Period</title>
        <description>Time to pericarditis recurrence (from randomization to 1st recurrence). Kaplan-Meier. Clinical Events Committee (CEC)-confirmed recurrences used for primary analysis. Recurrence defined as recurrence typical pericarditis pain with supportive objective evidence. CEC-adjudicated recurrences defined as:1) Re-appearance/worsening pericarditis pain (1 NRS ≥ 4) AND elevated CRP (≥1.0 mg/dL) on same day/separated by ≤ 7 days OR 2) Re-appearance/worsening pericarditis pain (1 NRS ≥ 4) AND abnormal CRP (&gt; 0.5 mg/dL) on same day/separated by ≤ 7 days AND 1 supportive evidence OR 3) Re-appearance/worsening pericarditis pain (no NRS ≥ 4) AND elevated CRP (≥ 1.0 mg/dL) not attributable to other causes AND 1 supportive evidence. Supportive evidence: White blood cell count &gt; upper limit normal, fever &gt; 38C, pericardial rub, electrocardiogram changes consistent with pericarditis, new/worsening pericardial effusion (echocardiogram), new/worsening pericardial inflammation (magnetic resonance imaging).</description>
        <time_frame>RW Period (mean 24.8 weeks)</time_frame>
        <population>Intent-to-Treat (ITT) Analysis Set: all participants who were randomized in the RW period.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Pericarditis Recurrence in the RW Period</title>
          <description>Time to pericarditis recurrence (from randomization to 1st recurrence). Kaplan-Meier. Clinical Events Committee (CEC)-confirmed recurrences used for primary analysis. Recurrence defined as recurrence typical pericarditis pain with supportive objective evidence. CEC-adjudicated recurrences defined as:1) Re-appearance/worsening pericarditis pain (1 NRS ≥ 4) AND elevated CRP (≥1.0 mg/dL) on same day/separated by ≤ 7 days OR 2) Re-appearance/worsening pericarditis pain (1 NRS ≥ 4) AND abnormal CRP (&gt; 0.5 mg/dL) on same day/separated by ≤ 7 days AND 1 supportive evidence OR 3) Re-appearance/worsening pericarditis pain (no NRS ≥ 4) AND elevated CRP (≥ 1.0 mg/dL) not attributable to other causes AND 1 supportive evidence. Supportive evidence: White blood cell count &gt; upper limit normal, fever &gt; 38C, pericardial rub, electrocardiogram changes consistent with pericarditis, new/worsening pericardial effusion (echocardiogram), new/worsening pericardial inflammation (magnetic resonance imaging).</description>
          <population>Intent-to-Treat (ITT) Analysis Set: all participants who were randomized in the RW period.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">The median was not reached due to low number of participants with an event at data cutoff.</measurement>
                    <measurement group_id="O2" value="8.6" lower_limit="4.0" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Two-sided p-value is from the log-rank test stratified by oral corticosteroid use at Run-In Baseline.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
            <estimate_desc>Calculated based on a Cox proportional-hazards model with treatment as covariate and stratified by oral corticosteroid use at run-in baseline.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Secondary Efficacy Endpoint: Percentage of Participants Who Maintained Clinical Response at Week 16 of the RW Period</title>
        <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Clinical response was defined as a weekly average of daily pericarditis pain on the NRS ≤ 2.0 and C-reactive protein (CRP) level ≤ 0.5 mg/dL, and on monotherapy of randomized study drug at Week 16.</description>
        <time_frame>RW Period Week 16</time_frame>
        <population>ITT Week 16 Analysis Set: All participants randomized at least 16 weeks before data cutoff.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Secondary Efficacy Endpoint: Percentage of Participants Who Maintained Clinical Response at Week 16 of the RW Period</title>
          <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Clinical response was defined as a weekly average of daily pericarditis pain on the NRS ≤ 2.0 and C-reactive protein (CRP) level ≤ 0.5 mg/dL, and on monotherapy of randomized study drug at Week 16.</description>
          <population>ITT Week 16 Analysis Set: All participants randomized at least 16 weeks before data cutoff.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O2" value="20.0" lower_limit="5.7" upper_limit="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>95% confidence interval (CI) and p-value were analyzed using a Cochran-Mantel-Haenszel test adjusted by oral corticosteroid use and diagnosis of recurrent idiopathic pericarditis at run-in baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>12.727</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.438</ci_lower_limit>
            <ci_upper_limit>66.428</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in percentages</param_type>
            <param_value>61.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>36.7</ci_lower_limit>
            <ci_upper_limit>85.2</ci_upper_limit>
            <estimate_desc>Differences between percentages are reported in percentage points. The 95% confidence intervals for the differences in percentages were based on a normal approximation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Secondary Efficacy Endpoint: Percentage of Days With No or Minimal Pericarditis Pain at Week 16 of the RW Period</title>
        <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. No or minimal pain was defined as non-missing NRS ≤ 2.&#xD;
The percentage of days with no or minimal pericarditis pain in the first 16 weeks was calculated for each participant using 16×7 as the denominator. Missing values in pain diary were counted as 0 day with no or minimal pain. Days of using oral rescue therapy or corticosteroid count as 0 day with no or minimal pain. If bailout rilonacept was used, each administration (loading dose or not) was counted as 7 days without qualifying no or minimal pain.</description>
        <time_frame>RW Period Week 16</time_frame>
        <population>ITT Week 16 Analysis Set: All participants randomized at least 16 weeks before data cutoff.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Secondary Efficacy Endpoint: Percentage of Days With No or Minimal Pericarditis Pain at Week 16 of the RW Period</title>
          <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. No or minimal pain was defined as non-missing NRS ≤ 2.&#xD;
The percentage of days with no or minimal pericarditis pain in the first 16 weeks was calculated for each participant using 16×7 as the denominator. Missing values in pain diary were counted as 0 day with no or minimal pain. Days of using oral rescue therapy or corticosteroid count as 0 day with no or minimal pain. If bailout rilonacept was used, each administration (loading dose or not) was counted as 7 days without qualifying no or minimal pain.</description>
          <population>ITT Week 16 Analysis Set: All participants randomized at least 16 weeks before data cutoff.</population>
          <units>percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" spread="7.45"/>
                    <measurement group_id="O2" value="45.9" spread="7.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Two-sided p-value calculated using analysis of covariance with treatment, randomization strata and run-in baseline NRS weekly average category (NRS ≤ 2 versus NRS &gt;2) as covariates.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares (LS) mean difference</param_type>
            <param_value>51.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>35.3</ci_lower_limit>
            <ci_upper_limit>68.4</ci_upper_limit>
            <estimate_desc>Least squares mean difference (rilonacept - placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Secondary Efficacy Endpoint: Percentage of Participants With Absent or Minimal Pericarditis Symptoms Based on the Patient Global Impression of Pericarditis Severity (PGIPS) at Week 16 of the RW Period</title>
        <description>Percentage of participants with no or minimal pericarditis symptoms at Week 16, based on the PGIPS, a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered using a 7-point rating scale ranging from absent (0=no recurrent pericarditis symptoms) to very severe (6=recurrent pericarditis symptoms that cannot be ignored and markedly limits daily activities).&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
        <time_frame>RW Period Week 16</time_frame>
        <population>ITT Week 16 Analysis Set: All participants randomized at least 16 weeks before data cutoff.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Secondary Efficacy Endpoint: Percentage of Participants With Absent or Minimal Pericarditis Symptoms Based on the Patient Global Impression of Pericarditis Severity (PGIPS) at Week 16 of the RW Period</title>
          <description>Percentage of participants with no or minimal pericarditis symptoms at Week 16, based on the PGIPS, a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered using a 7-point rating scale ranging from absent (0=no recurrent pericarditis symptoms) to very severe (6=recurrent pericarditis symptoms that cannot be ignored and markedly limits daily activities).&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
          <population>ITT Week 16 Analysis Set: All participants randomized at least 16 weeks before data cutoff.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O2" value="25.0" lower_limit="8.7" upper_limit="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>95% CI and p-value are analyzed using a Cochran-Mantel-Haenszel test adjusted by oral corticosteroid use and diagnosis of recurrent idiopathic pericarditis at RI baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>10.000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.136</ci_lower_limit>
            <ci_upper_limit>46.826</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in percentages</param_type>
            <param_value>56.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>30.6</ci_lower_limit>
            <ci_upper_limit>81.3</ci_upper_limit>
            <estimate_desc>Differences between percentages are reported in percentage points. The 95% confidence intervals for the differences in percentages were based on a normal approximation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Maintained Clinical Response at Week 24 of the RW Period</title>
        <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Clinical response was defined as a weekly average of daily pericarditis pain on the NRS ≤ 2.0 and C-reactive protein (CRP) level ≤ 0.5 mg/dL, and on monotherapy of randomized study drug at Week 24.</description>
        <time_frame>RW Period Week 24</time_frame>
        <population>ITT Week 24 Analysis Set: All participants randomized at least 24 weeks before data cutoff.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Maintained Clinical Response at Week 24 of the RW Period</title>
          <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Clinical response was defined as a weekly average of daily pericarditis pain on the NRS ≤ 2.0 and C-reactive protein (CRP) level ≤ 0.5 mg/dL, and on monotherapy of randomized study drug at Week 24.</description>
          <population>ITT Week 24 Analysis Set: All participants randomized at least 24 weeks before data cutoff.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" lower_limit="50.1" upper_limit="93.2"/>
                    <measurement group_id="O2" value="20.0" lower_limit="4.3" upper_limit="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0022</p_value>
            <p_value_desc>95% CI and p-value were analyzed using a Cochran-Mantel-Haenszel test adjusted by oral corticosteroid use and diagnosis of recurrent idiopathic pericarditis at run-in baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>8.370</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.317</ci_lower_limit>
            <ci_upper_limit>53.188</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Maintained Clinical Response at Week 8 of the RW Period</title>
        <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Clinical response was defined as a weekly average of daily pericarditis pain on the NRS ≤ 2.0 and C-reactive protein (CRP) level ≤ 0.5 mg/dL, and on monotherapy of randomized study drug at Week 8.</description>
        <time_frame>RW Period Week 8</time_frame>
        <population>ITT Week 8 Analysis Set: All participants randomized at least 8 weeks before data cutoff.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Maintained Clinical Response at Week 8 of the RW Period</title>
          <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Clinical response was defined as a weekly average of daily pericarditis pain on the NRS ≤ 2.0 and C-reactive protein (CRP) level ≤ 0.5 mg/dL, and on monotherapy of randomized study drug at Week 8.</description>
          <population>ITT Week 8 Analysis Set: All participants randomized at least 8 weeks before data cutoff.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="57.7" upper_limit="91.4"/>
                    <measurement group_id="O2" value="25.8" lower_limit="11.9" upper_limit="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>95% CI and p-value were analyzed using a Cochran-Mantel-Haenszel test adjusted by oral corticosteroid use and diagnosis of recurrent idiopathic pericarditis at run-in baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>10.906</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.051</ci_lower_limit>
            <ci_upper_limit>38.981</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With No or Minimal Pericarditis Pain at Week 24 of the RW Period</title>
        <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. No or minimal pain was defined as non-missing NRS ≤ 2.&#xD;
The percentage of days with no or minimal pericarditis pain in the first 24 weeks was calculated for each participant using 24×7 as the denominator. Missing values in pain diary were counted as 0 day with no or minimal pain. Days of using oral rescue therapy or corticosteroid count as 0 day with no or minimal pain. If bailout rilonacept was used, each administration (loading dose or not) was counted as 7 days without qualifying no or minimal pain.</description>
        <time_frame>RW Period Week 24</time_frame>
        <population>ITT Week 24 Analysis Set: All participants randomized at least 24 weeks before data cutoff.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With No or Minimal Pericarditis Pain at Week 24 of the RW Period</title>
          <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. No or minimal pain was defined as non-missing NRS ≤ 2.&#xD;
The percentage of days with no or minimal pericarditis pain in the first 24 weeks was calculated for each participant using 24×7 as the denominator. Missing values in pain diary were counted as 0 day with no or minimal pain. Days of using oral rescue therapy or corticosteroid count as 0 day with no or minimal pain. If bailout rilonacept was used, each administration (loading dose or not) was counted as 7 days without qualifying no or minimal pain.</description>
          <population>ITT Week 24 Analysis Set: All participants randomized at least 24 weeks before data cutoff.</population>
          <units>percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.9" spread="7.93"/>
                    <measurement group_id="O2" value="47.5" spread="7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Two-sided p-value calculated using analysis of covariance with treatment, randomization strata and run-in baseline NRS weekly average category (NRS ≤ 2 versus NRS &gt;2) as covariates.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>52.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>34.5</ci_lower_limit>
            <ci_upper_limit>70.4</ci_upper_limit>
            <estimate_desc>Least squares mean difference (rilonacept - placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With No or Minimal Pericarditis Pain at Week 8 of the RW Period</title>
        <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. No or minimal pain was defined as non-missing NRS ≤ 2.&#xD;
The percentage of days with no or minimal pericarditis pain in the first 24 weeks was calculated for each participant using 8×7 as the denominator. Missing values in pain diary were counted as 0 day with no or minimal pain. Days of using oral rescue therapy or corticosteroid count as 0 day with no or minimal pain. If bailout rilonacept was used, each administration (loading dose or not) was counted as 7 days without qualifying no or minimal pain.</description>
        <time_frame>RW Period Week 8</time_frame>
        <population>ITT Week 8 Analysis Set: All participants randomized at least 8 weeks before data cutoff.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With No or Minimal Pericarditis Pain at Week 8 of the RW Period</title>
          <description>Participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. No or minimal pain was defined as non-missing NRS ≤ 2.&#xD;
The percentage of days with no or minimal pericarditis pain in the first 24 weeks was calculated for each participant using 8×7 as the denominator. Missing values in pain diary were counted as 0 day with no or minimal pain. Days of using oral rescue therapy or corticosteroid count as 0 day with no or minimal pain. If bailout rilonacept was used, each administration (loading dose or not) was counted as 7 days without qualifying no or minimal pain.</description>
          <population>ITT Week 8 Analysis Set: All participants randomized at least 8 weeks before data cutoff.</population>
          <units>percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" spread="7.34"/>
                    <measurement group_id="O2" value="55.7" spread="6.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Two-sided p-value calculated using analysis of covariance with treatment, randomization strata and run-in baseline NRS weekly average category (NRS ≤ 2 versus NRS &gt;2) as covariates.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>39.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.0</ci_lower_limit>
            <ci_upper_limit>54.4</ci_upper_limit>
            <estimate_desc>Least squares mean difference (rilonacept - placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Absent or Minimal Pericarditis Symptoms at Week 24 of the RW Period Based on the PGIPS</title>
        <description>Percentage of participants with no or minimal pericarditis symptoms at Week 24, based on the PGIPS, a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered using a 7-point rating scale ranging from absent (0=no recurrent pericarditis symptoms) to very severe (6=recurrent pericarditis symptoms cannot be ignored and markedly limits daily activities).&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
        <time_frame>RW Period Week 24</time_frame>
        <population>ITT Week 24 Analysis Set: All participants randomized at least 24 weeks before data cutoff.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Absent or Minimal Pericarditis Symptoms at Week 24 of the RW Period Based on the PGIPS</title>
          <description>Percentage of participants with no or minimal pericarditis symptoms at Week 24, based on the PGIPS, a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered using a 7-point rating scale ranging from absent (0=no recurrent pericarditis symptoms) to very severe (6=recurrent pericarditis symptoms cannot be ignored and markedly limits daily activities).&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
          <population>ITT Week 24 Analysis Set: All participants randomized at least 24 weeks before data cutoff.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2" lower_limit="63.6" upper_limit="98.5"/>
                    <measurement group_id="O2" value="20.0" lower_limit="4.3" upper_limit="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>95% CI and p-value are analyzed using a Cochran-Mantel-Haenszel (CMH) test adjusted by oral corticosteroid use at RI baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>30.522</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.262</ci_lower_limit>
            <ci_upper_limit>218.552</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Absent or Minimal Pericarditis Symptoms at Week 8 of the RW Period Based on the PGIPS</title>
        <description>Percentage of participants with no or minimal pericarditis symptoms at Week 16, based on the Patient Global Impression of Pericarditis Severity (PGI-PS). The PGI-PS is a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered, using a 7-point rating scale ranging from absent (no recurrent pericarditis symptoms) to very severe (recurrent pericarditis symptoms cannot be ignored).&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
        <time_frame>RW Period Week 8</time_frame>
        <population>ITT Week 8 Analysis Set: All participants randomized at least 8 weeks before data cutoff.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Absent or Minimal Pericarditis Symptoms at Week 8 of the RW Period Based on the PGIPS</title>
          <description>Percentage of participants with no or minimal pericarditis symptoms at Week 16, based on the Patient Global Impression of Pericarditis Severity (PGI-PS). The PGI-PS is a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered, using a 7-point rating scale ranging from absent (no recurrent pericarditis symptoms) to very severe (recurrent pericarditis symptoms cannot be ignored).&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
          <population>ITT Week 8 Analysis Set: All participants randomized at least 8 weeks before data cutoff.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.2" lower_limit="66.3" upper_limit="95.8"/>
                    <measurement group_id="O2" value="32.3" lower_limit="16.7" upper_limit="51.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>95% CI and p-value are analyzed using a Cochran-Mantel-Haenszel test adjusted by oral corticosteroid use and diagnosis of recurrent idiopathic pericarditis at RI baseline.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>14.432</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.439</ci_lower_limit>
            <ci_upper_limit>60.574</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Without Pericarditis Recurrence in the First 24 Weeks of the RW Period</title>
        <description>Pericarditis recurrence is defined as the recurrence of typical pericarditis pain associated with supportive objective evidence of pericarditis. At any time during the RW period, participants who experienced a suspected recurrence of pericarditis symptoms reported to the study site/clinic for a scheduled or unscheduled visit, during which clinical assessments were performed to gather all the necessary diagnostic data to confirm or rule out the presence of pericarditis recurrence. A pericarditis recurrence event adjudication package was then prepared for adjudication by CEC. Kaplan-Meier estimate.</description>
        <time_frame>up to 24 weeks in the RW Period</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Without Pericarditis Recurrence in the First 24 Weeks of the RW Period</title>
          <description>Pericarditis recurrence is defined as the recurrence of typical pericarditis pain associated with supportive objective evidence of pericarditis. At any time during the RW period, participants who experienced a suspected recurrence of pericarditis symptoms reported to the study site/clinic for a scheduled or unscheduled visit, during which clinical assessments were performed to gather all the necessary diagnostic data to confirm or rule out the presence of pericarditis recurrence. A pericarditis recurrence event adjudication package was then prepared for adjudication by CEC. Kaplan-Meier estimate.</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="72.9" upper_limit="99.4"/>
                    <measurement group_id="O2" value="19.9" lower_limit="6.5" upper_limit="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>normal approximation</method>
            <param_type>Difference</param_type>
            <param_value>75.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>56.8</ci_lower_limit>
            <ci_upper_limit>94.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Pericarditis Pain ≥ 4 on the NRS in the RW Period</title>
        <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'.</description>
        <time_frame>RW Period (mean 24.8 weeks)</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Pericarditis Pain ≥ 4 on the NRS in the RW Period</title>
          <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'.</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="33.1" upper_limit="NA">Median not reached due to low events.</measurement>
                    <measurement group_id="O2" value="4.1" lower_limit="2.9" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Two-sided p-value is from the log-rank test stratified by oral corticosteroid use at run-in baseline.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
            <estimate_desc>Calculated based on a Cox proportional hazards model with treatment as covariate and stratified by oral corticosteroid use at run-in baseline.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to CRP Level ≥ 1 mg/dL in the RW Period</title>
        <description>Kaplan-Meier estimate.</description>
        <time_frame>RW Period (mean 24.8 weeks)</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to CRP Level ≥ 1 mg/dL in the RW Period</title>
          <description>Kaplan-Meier estimate.</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median not reached due to low number of participants with CRP ≥ 1 mg/dL.</measurement>
                    <measurement group_id="O2" value="6.9" lower_limit="4.0" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Two-sided p-value is from the log-rank test stratified by oral corticosteroid use at run-in baseline.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
            <estimate_desc>Calculated based on a Cox proportional hazards model with treatment as covariate and stratified by oral corticosteroid use at run-in baseline.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Pericardial Rub in the RW Period</title>
        <description>Kaplan-Meier estimate. A pericardial rub (also called a pericardial friction rub) is an audible medical sign used in the diagnosis of pericarditis.</description>
        <time_frame>RW Period (mean 24.8 weeks)</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Pericardial Rub in the RW Period</title>
          <description>Kaplan-Meier estimate. A pericardial rub (also called a pericardial friction rub) is an audible medical sign used in the diagnosis of pericarditis.</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Not estimable due to low number of participants with an event.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not estimable due to low number of participants with an event.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7447</p_value>
            <p_value_desc>Two-sided p-value is from the log-rank test without stratification by randomization strata.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>4.46</ci_upper_limit>
            <estimate_desc>Calculated based on a Cox proportional-hazards model with treatment as covariate and without stratification by randomization strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Widespread ST-segment Elevation or PR-segment Depression on Electrocardiogram (ECG) in the RW Period</title>
        <description>Kaplan-Meier estimate. ST-segment elevation and PR-segment depression are ECG changes in the evolution of acute pericarditis.</description>
        <time_frame>RW Period (mean 24.8 weeks)</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Widespread ST-segment Elevation or PR-segment Depression on Electrocardiogram (ECG) in the RW Period</title>
          <description>Kaplan-Meier estimate. ST-segment elevation and PR-segment depression are ECG changes in the evolution of acute pericarditis.</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Not estimable due to low number of participants with an event.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not estimable due to low number of participants with an event.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1913</p_value>
            <p_value_desc>Two-sided p-value is from the log-rank test without stratification by randomization strata.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
            <estimate_desc>Calculated based on a Cox proportional-hazards model with treatment as covariate and without stratification by randomization strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to New or Worsening Pericardial Effusion on Echocardiography (ECHO) in the RW Period</title>
        <description>Pericardial effusion based on ECHO was evaluated by the central laboratory during the RW period. Kaplan-Meier estimate.</description>
        <time_frame>RW Period (mean 24.8 weeks)</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to New or Worsening Pericardial Effusion on Echocardiography (ECHO) in the RW Period</title>
          <description>Pericardial effusion based on ECHO was evaluated by the central laboratory during the RW period. Kaplan-Meier estimate.</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Not estimable due to low number of participants with an event.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not estimable due to low number of participants with an event.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0059</p_value>
            <p_value_desc>Two-sided p-value is from the log-rank test without stratification by randomization strata.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit_na_comment>Not estimable due to low number of participants with an event.</ci_upper_limit_na_comment>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in ECHO Pericardial Effusion Size Categories at RW Period Baseline, RW Week 24 and Worst Post-baseline in the RW Period</title>
        <description>Pericardial effusion based on ECHO was evaluated by the central laboratory during the RW period. &quot;None or trivial/physiologic&quot; is considered to be normal. The &quot;RW Worst Post-baseline&quot; category denotes the largest size of pericardial effusion category in which a participant was reported at any time during the RW period (post-baseline).</description>
        <time_frame>RW Period Baseline, RW Period Week 24, RW Period (mean 24.8 weeks)</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants with a non-missing value at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept, Before Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Rilonacept, Including Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
          <group group_id="O3">
            <title>Randomized Withdrawal Period: Placebo, Before Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
          <group group_id="O4">
            <title>Randomized Withdrawal Period: Placebo, Including Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in ECHO Pericardial Effusion Size Categories at RW Period Baseline, RW Week 24 and Worst Post-baseline in the RW Period</title>
          <description>Pericardial effusion based on ECHO was evaluated by the central laboratory during the RW period. &quot;None or trivial/physiologic&quot; is considered to be normal. The &quot;RW Worst Post-baseline&quot; category denotes the largest size of pericardial effusion category in which a participant was reported at any time during the RW period (post-baseline).</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants with a non-missing value at given time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RW Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None or Trivial/Physiologic</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Small</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Large</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Large</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing/Not Done</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RW Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None or Trivial/Physiologic</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Small</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Large</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Large</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing/Not Done</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RW Worst Post-baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None or Trivial/Physiologic</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Small</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Large</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Large</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing/Not Done</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From RW Period Baseline Over Time in CRP Levels in RW Period</title>
        <description>Estimated from ANCOVA models including treatment arm as fix effect, baseline value, baseline value by treatment interaction, randomization strata as covariates.</description>
        <time_frame>RW Period Baseline, RW Period Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, 56</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants with a non-missing value at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept, Before Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Rilonacept, Including Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
          <group group_id="O3">
            <title>Randomized Withdrawal Period: Placebo, Before Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
          <group group_id="O4">
            <title>Randomized Withdrawal Period: Placebo, Including Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From RW Period Baseline Over Time in CRP Levels in RW Period</title>
          <description>Estimated from ANCOVA models including treatment arm as fix effect, baseline value, baseline value by treatment interaction, randomization strata as covariates.</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants with a non-missing value at given time point.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at RW Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.058"/>
                    <measurement group_id="O2" value="-0.05" spread="1.112"/>
                    <measurement group_id="O3" value="0.15" spread="0.061"/>
                    <measurement group_id="O4" value="1.46" spread="0.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.308"/>
                    <measurement group_id="O2" value="0.11" spread="0.300"/>
                    <measurement group_id="O3" value="0.45" spread="0.331"/>
                    <measurement group_id="O4" value="0.25" spread="0.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.034"/>
                    <measurement group_id="O2" value="-0.04" spread="0.085"/>
                    <measurement group_id="O3" value="0.03" spread="0.043"/>
                    <measurement group_id="O4" value="0.08" spread="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.148"/>
                    <measurement group_id="O2" value="0.27" spread="0.119"/>
                    <measurement group_id="O3" value="0.04" spread="0.227"/>
                    <measurement group_id="O4" value="0.18" spread="0.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.048"/>
                    <measurement group_id="O2" value="-0.10" spread="0.181"/>
                    <measurement group_id="O3" value="0.10" spread="0.083"/>
                    <measurement group_id="O4" value="0.16" spread="0.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.032"/>
                    <measurement group_id="O2" value="-0.05" spread="0.047"/>
                    <measurement group_id="O3" value="0.06" spread="0.056"/>
                    <measurement group_id="O4" value="0.02" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.016"/>
                    <measurement group_id="O2" value="-0.02" spread="0.059"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.07" spread="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.010"/>
                    <measurement group_id="O2" value="0.08" spread="0.298"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.74" spread="0.290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.000"/>
                    <measurement group_id="O2" value="-0.03" spread="0.008"/>
                    <measurement group_id="O4" value="0.06" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.00" spread="NA">1 participant in arm at time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From RW Period Baseline Over Time in Weekly Average of Pericarditis Pain in the RW Period</title>
        <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Estimated from ANCOVA models including treatment arm as fix effect, baseline value, baseline value by treatment interaction, randomization strata as covariates.</description>
        <time_frame>RW Period Baseline, RW Period Weeks 1-50, 54</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants with a non-missing value at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept, Before Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Rilonacept, Including Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
          <group group_id="O3">
            <title>Randomized Withdrawal Period: Placebo, Before Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
          <group group_id="O4">
            <title>Randomized Withdrawal Period: Placebo, Including Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From RW Period Baseline Over Time in Weekly Average of Pericarditis Pain in the RW Period</title>
          <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Estimated from ANCOVA models including treatment arm as fix effect, baseline value, baseline value by treatment interaction, randomization strata as covariates.</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants with a non-missing value at given time point.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at RW Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.109"/>
                    <measurement group_id="O2" value="-0.02" spread="0.109"/>
                    <measurement group_id="O3" value="0.23" spread="0.109"/>
                    <measurement group_id="O4" value="0.23" spread="0.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.261"/>
                    <measurement group_id="O2" value="-0.18" spread="0.300"/>
                    <measurement group_id="O3" value="0.63" spread="0.252"/>
                    <measurement group_id="O4" value="0.75" spread="0.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.320"/>
                    <measurement group_id="O2" value="-0.25" spread="0.354"/>
                    <measurement group_id="O3" value="1.08" spread="0.285"/>
                    <measurement group_id="O4" value="1.23" spread="0.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.322"/>
                    <measurement group_id="O2" value="-0.11" spread="0.468"/>
                    <measurement group_id="O3" value="1.05" spread="0.333"/>
                    <measurement group_id="O4" value="1.84" spread="0.428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.314"/>
                    <measurement group_id="O2" value="-0.21" spread="0.351"/>
                    <measurement group_id="O3" value="1.27" spread="0.332"/>
                    <measurement group_id="O4" value="1.34" spread="0.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.296"/>
                    <measurement group_id="O2" value="0.02" spread="0.310"/>
                    <measurement group_id="O3" value="0.96" spread="0.290"/>
                    <measurement group_id="O4" value="0.84" spread="0.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.272"/>
                    <measurement group_id="O2" value="0.12" spread="0.247"/>
                    <measurement group_id="O3" value="0.88" spread="0.303"/>
                    <measurement group_id="O4" value="0.86" spread="0.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.226"/>
                    <measurement group_id="O2" value="0.11" spread="0.205"/>
                    <measurement group_id="O3" value="0.77" spread="0.253"/>
                    <measurement group_id="O4" value="0.58" spread="0.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.310"/>
                    <measurement group_id="O2" value="0.05" spread="0.320"/>
                    <measurement group_id="O3" value="1.45" spread="0.402"/>
                    <measurement group_id="O4" value="1.10" spread="0.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.270"/>
                    <measurement group_id="O2" value="-0.21" spread="0.262"/>
                    <measurement group_id="O3" value="1.11" spread="0.343"/>
                    <measurement group_id="O4" value="0.62" spread="0.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.200"/>
                    <measurement group_id="O2" value="-0.16" spread="0.272"/>
                    <measurement group_id="O3" value="0.43" spread="0.267"/>
                    <measurement group_id="O4" value="0.46" spread="0.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.174"/>
                    <measurement group_id="O2" value="-0.03" spread="0.248"/>
                    <measurement group_id="O3" value="0.36" spread="0.235"/>
                    <measurement group_id="O4" value="0.32" spread="0.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.331"/>
                    <measurement group_id="O2" value="0.06" spread="0.256"/>
                    <measurement group_id="O3" value="0.25" spread="0.386"/>
                    <measurement group_id="O4" value="0.07" spread="0.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.186"/>
                    <measurement group_id="O2" value="0.08" spread="0.185"/>
                    <measurement group_id="O3" value="0.24" spread="0.262"/>
                    <measurement group_id="O4" value="0.06" spread="0.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.097"/>
                    <measurement group_id="O2" value="0.15" spread="0.148"/>
                    <measurement group_id="O3" value="-0.11" spread="0.215"/>
                    <measurement group_id="O4" value="0.16" spread="0.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.110"/>
                    <measurement group_id="O2" value="-0.07" spread="0.167"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.09" spread="0.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.129"/>
                    <measurement group_id="O2" value="0.01" spread="0.183"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.05" spread="0.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.149"/>
                    <measurement group_id="O2" value="0.05" spread="0.157"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="-0.05" spread="0.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.149"/>
                    <measurement group_id="O2" value="-0.05" spread="0.167"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="-0.04" spread="0.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.111"/>
                    <measurement group_id="O2" value="-0.22" spread="0.228"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.30" spread="0.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.156"/>
                    <measurement group_id="O2" value="0.02" spread="0.162"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.23" spread="0.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.097"/>
                    <measurement group_id="O2" value="-0.12" spread="0.124"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.01" spread="0.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.103"/>
                    <measurement group_id="O2" value="-0.03" spread="0.145"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="-0.01" spread="0.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.122"/>
                    <measurement group_id="O2" value="-0.04" spread="0.138"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.02" spread="0.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.122"/>
                    <measurement group_id="O2" value="0.09" spread="0.109"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.13" spread="0.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.145"/>
                    <measurement group_id="O2" value="0.16" spread="0.127"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.29" spread="0.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.193"/>
                    <measurement group_id="O2" value="0.16" spread="0.154"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.15" spread="0.157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.449"/>
                    <measurement group_id="O2" value="0.33" spread="0.339"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.18" spread="0.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.160"/>
                    <measurement group_id="O2" value="0.29" spread="0.233"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.12" spread="0.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.296"/>
                    <measurement group_id="O2" value="0.39" spread="0.259"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.64" spread="0.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.110"/>
                    <measurement group_id="O2" value="0.02" spread="0.109"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.33" spread="0.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.081"/>
                    <measurement group_id="O2" value="0.20" spread="0.141"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.23" spread="0.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.016"/>
                    <measurement group_id="O2" value="0.31" spread="0.167"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.20" spread="0.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 34</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.086"/>
                    <measurement group_id="O2" value="0.95" spread="0.387"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.27" spread="0.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.055"/>
                    <measurement group_id="O2" value="0.62" spread="0.347"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.11" spread="0.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.093"/>
                    <measurement group_id="O2" value="0.15" spread="0.348"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.20" spread="0.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 37</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.243"/>
                    <measurement group_id="O2" value="-0.13" spread="0.404"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.16" spread="0.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 38</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.022"/>
                    <measurement group_id="O2" value="0.40" spread="0.177"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.04" spread="0.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="0.260"/>
                    <measurement group_id="O2" value="0.55" spread="0.578"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.51" spread="0.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O2" value="0.17" spread="1.253"/>
                    <measurement group_id="O3" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                    <measurement group_id="O4" value="0.44" spread="1.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 41</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.293"/>
                    <measurement group_id="O2" value="0.72" spread="0.723"/>
                    <measurement group_id="O4" value="0.91" spread="0.939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.488"/>
                    <measurement group_id="O2" value="0.79" spread="0.262"/>
                    <measurement group_id="O4" value="0.60" spread="0.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="0.619"/>
                    <measurement group_id="O2" value="0.87" spread="0.449"/>
                    <measurement group_id="O4" value="0.88" spread="0.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.553"/>
                    <measurement group_id="O2" value="0.64" spread="0.590"/>
                    <measurement group_id="O4" value="0.75" spread="0.766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.567"/>
                    <measurement group_id="O2" value="0.85" spread="0.384"/>
                    <measurement group_id="O4" value="3.77" spread="1.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 46</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.680"/>
                    <measurement group_id="O2" value="0.39" spread="0.471"/>
                    <measurement group_id="O4" value="NA" spread="NA">Not estimable due to SAS algorithms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 47</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.000"/>
                    <measurement group_id="O2" value="0.16" spread="0.261"/>
                    <measurement group_id="O4" value="3.10" spread="1.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.000"/>
                    <measurement group_id="O2" value="0.32" spread="0.273"/>
                    <measurement group_id="O4" value="6.18" spread="1.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 49</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.000"/>
                    <measurement group_id="O2" value="-0.13" spread="0.115"/>
                    <measurement group_id="O4" value="5.77" spread="0.630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="NA">1 participant</measurement>
                    <measurement group_id="O2" value="0.00" spread="NA">1 participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.58" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Absent or Minimal Pericarditis Symptoms Over Time After RW Period Week 24 Based on the PGIPS</title>
        <description>The PGIPS, a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered using a 7-point rating scale ranging from absent (0=no recurrent pericarditis symptoms) to very severe (6=recurrent pericarditis symptoms cannot be ignored and markedly limits daily activities).&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
        <time_frame>RW Period Weeks 32, 40, 48, 56</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants with a non-missing value at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept, Before Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Rilonacept, Including Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
          <group group_id="O3">
            <title>Randomized Withdrawal Period: Placebo, Before Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
          <group group_id="O4">
            <title>Randomized Withdrawal Period: Placebo, Including Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Absent or Minimal Pericarditis Symptoms Over Time After RW Period Week 24 Based on the PGIPS</title>
          <description>The PGIPS, a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered using a 7-point rating scale ranging from absent (0=no recurrent pericarditis symptoms) to very severe (6=recurrent pericarditis symptoms cannot be ignored and markedly limits daily activities).&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants with a non-missing value at given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="58.72" upper_limit="99.77"/>
                    <measurement group_id="O2" value="83.3" lower_limit="51.59" upper_limit="97.91"/>
                    <measurement group_id="O3" value="50.0" lower_limit="1.26" upper_limit="98.74"/>
                    <measurement group_id="O4" value="70.0" lower_limit="34.75" upper_limit="93.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="14.66" upper_limit="94.73"/>
                    <measurement group_id="O2" value="66.7" lower_limit="22.28" upper_limit="95.67"/>
                    <measurement group_id="O3" value="100" lower_limit="2.50" upper_limit="100.00"/>
                    <measurement group_id="O4" value="83.3" lower_limit="35.88" upper_limit="99.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="15.81" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100" lower_limit="15.81" upper_limit="100.00"/>
                    <measurement group_id="O4" value="50.0" lower_limit="1.26" upper_limit="98.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="100" lower_limit="2.50" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Absent or Minimal Pericarditis Activity Over Time in the RW Period Based on the Physician Global Assessment of Pericarditis Activity (PGA-PA)</title>
        <description>The PGA-PA is a single-item, clinician-reported outcome measure that Investigators use to rate their impression of the patient's overall pericarditis disease activity at the time the assessment is completed, using a rating scale ranging from absent to very severe. The Investigator selected the box that best described a participant's pericarditis activity at the time of occurrence of the assessment: Absent, Minimal, Mild, Moderate, Moderately Severe, Severe, Very Severe.</description>
        <time_frame>RW Period Baseline, RW Period Weeks 8, 16, 24, 32, 40, 48, 56</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants with a non-missing value at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept, Before Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Rilonacept, Including Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
          <group group_id="O3">
            <title>Randomized Withdrawal Period: Placebo, Before Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
          <group group_id="O4">
            <title>Randomized Withdrawal Period: Placebo, Including Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Absent or Minimal Pericarditis Activity Over Time in the RW Period Based on the Physician Global Assessment of Pericarditis Activity (PGA-PA)</title>
          <description>The PGA-PA is a single-item, clinician-reported outcome measure that Investigators use to rate their impression of the patient's overall pericarditis disease activity at the time the assessment is completed, using a rating scale ranging from absent to very severe. The Investigator selected the box that best described a participant's pericarditis activity at the time of occurrence of the assessment: Absent, Minimal, Mild, Moderate, Moderately Severe, Severe, Very Severe.</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants with a non-missing value at given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="82.78" upper_limit="99.92"/>
                    <measurement group_id="O2" value="96.7" lower_limit="82.78" upper_limit="99.92"/>
                    <measurement group_id="O3" value="100" lower_limit="88.78" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100" lower_limit="88.78" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="85.18" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100" lower_limit="85.18" upper_limit="100.00"/>
                    <measurement group_id="O3" value="71.4" lower_limit="41.90" upper_limit="91.61"/>
                    <measurement group_id="O4" value="85.2" lower_limit="66.27" upper_limit="95.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0" lower_limit="75.13" upper_limit="99.87"/>
                    <measurement group_id="O2" value="95.0" lower_limit="75.13" upper_limit="99.87"/>
                    <measurement group_id="O3" value="100" lower_limit="47.82" upper_limit="100.00"/>
                    <measurement group_id="O4" value="95.0" lower_limit="75.13" upper_limit="99.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="78.20" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100" lower_limit="78.20" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100" lower_limit="29.24" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100" lower_limit="76.84" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="58.72" upper_limit="99.77"/>
                    <measurement group_id="O2" value="83.3" lower_limit="51.59" upper_limit="97.91"/>
                    <measurement group_id="O3" value="50.0" lower_limit="1.26" upper_limit="98.74"/>
                    <measurement group_id="O4" value="90.9" lower_limit="58.72" upper_limit="99.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="9.43" upper_limit="99.16"/>
                    <measurement group_id="O2" value="75.0" lower_limit="19.41" upper_limit="99.37"/>
                    <measurement group_id="O3" value="100" lower_limit="2.50" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100" lower_limit="54.07" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="1.26" upper_limit="98.74"/>
                    <measurement group_id="O2" value="50.0" lower_limit="1.26" upper_limit="98.74"/>
                    <measurement group_id="O4" value="50.0" lower_limit="1.26" upper_limit="98.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="100" lower_limit="2.50" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From RW Period Baseline in Short Form-36 (SF-36) Physical and Mental Component Scores at RW Period Week 24</title>
        <description>The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the physical component summary (PCS) score of the SF-36. Items 5-8 primarily contribute to the mental component summary (MCS) score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best) with higher scores indicating better health. Increases from baseline indicate improvement.</description>
        <time_frame>RW Period Baseline, RW Period Week 24</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants 18 years and older with a non-missing value at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept, Before Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Rilonacept, Including Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
          <group group_id="O3">
            <title>Randomized Withdrawal Period: Placebo, Before Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
          <group group_id="O4">
            <title>Randomized Withdrawal Period: Placebo, Including Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From RW Period Baseline in Short Form-36 (SF-36) Physical and Mental Component Scores at RW Period Week 24</title>
          <description>The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the physical component summary (PCS) score of the SF-36. Items 5-8 primarily contribute to the mental component summary (MCS) score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best) with higher scores indicating better health. Increases from baseline indicate improvement.</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants 18 years and older with a non-missing value at given time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at RW Week 24 in PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.427" spread="5.8566"/>
                    <measurement group_id="O2" value="0.427" spread="5.8566"/>
                    <measurement group_id="O3" value="0.363" spread="2.3866"/>
                    <measurement group_id="O4" value="0.354" spread="2.7169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 24 in MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.081" spread="11.3204"/>
                    <measurement group_id="O2" value="3.081" spread="11.3204"/>
                    <measurement group_id="O3" value="-0.050" spread="2.7318"/>
                    <measurement group_id="O4" value="-0.575" spread="5.5922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From RW Baseline in SF-36 Individual Scores at RW Period Week 24</title>
        <description>The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scores on each item are summed and averaged (range: 0=worst to 100=best) with higher scores indicating better health. Increases from baseline indicate improvement.</description>
        <time_frame>RW Period Baseline, RW Period Week 24</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants 18 years and older with a non-missing value at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept, Before Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Rilonacept, Including Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
          <group group_id="O3">
            <title>Randomized Withdrawal Period: Placebo, Before Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
          <group group_id="O4">
            <title>Randomized Withdrawal Period: Placebo, Including Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From RW Baseline in SF-36 Individual Scores at RW Period Week 24</title>
          <description>The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scores on each item are summed and averaged (range: 0=worst to 100=best) with higher scores indicating better health. Increases from baseline indicate improvement.</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants 18 years and older with a non-missing value at given time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at RW Week 24 in Physical Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.427" spread="5.3887"/>
                    <measurement group_id="O2" value="2.427" spread="5.3887"/>
                    <measurement group_id="O3" value="-0.637" spread="1.1027"/>
                    <measurement group_id="O4" value="0.273" spread="4.0332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 24 in Role Physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.995" spread="5.7997"/>
                    <measurement group_id="O2" value="2.995" spread="5.7997"/>
                    <measurement group_id="O3" value="1.500" spread="2.5981"/>
                    <measurement group_id="O4" value="1.123" spread="3.4967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 24 in Bodily Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.485" spread="9.7799"/>
                    <measurement group_id="O2" value="-0.485" spread="9.7799"/>
                    <measurement group_id="O3" value="0.807" spread="5.2864"/>
                    <measurement group_id="O4" value="0.921" spread="6.2063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 24 in General Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.919" spread="4.9051"/>
                    <measurement group_id="O2" value="-0.919" spread="4.9051"/>
                    <measurement group_id="O3" value="-1.587" spread="5.9895"/>
                    <measurement group_id="O4" value="-1.901" spread="6.8070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 24 in Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.168" spread="9.8845"/>
                    <measurement group_id="O2" value="3.168" spread="9.8845"/>
                    <measurement group_id="O3" value="1.980" spread="6.8589"/>
                    <measurement group_id="O4" value="0.636" spread="6.1850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 24 in Social Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.669" spread="8.6544"/>
                    <measurement group_id="O2" value="0.669" spread="8.6544"/>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                    <measurement group_id="O4" value="-1.791" spread="4.2209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 24 in Role Emotional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.251" spread="10.7297"/>
                    <measurement group_id="O2" value="3.251" spread="10.7297"/>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                    <measurement group_id="O4" value="0.249" spread="7.0264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 24 in Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.314" spread="8.5900"/>
                    <measurement group_id="O2" value="3.314" spread="8.5900"/>
                    <measurement group_id="O3" value="-0.873" spread="3.9923"/>
                    <measurement group_id="O4" value="-0.187" spread="6.7646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From RW Period Baseline in the Short Form Health Survey-6 Domains (SF-6D) Utility Index Score at RW Period Week 24</title>
        <description>The SF-6D is calculated based on responses to 11 items on the SF-36, that correspond to 6 domains: physical functioning, role participation (combined role-physical and role-emotional), social functioning, bodily pain, mental health, and vitality. Individual respondents can be classified on any of 4 to 6 levels of functioning or limitations for each of 6 domains, thus allowing a respondent to be classified into any of 18,000 possible unique health states. Using a standard gamble technique, each of these health states were mapped onto the SF-6D index score, which ranges from 0.00 (worst possible health state/death) to 1.00 (best possible health state/perfect health).</description>
        <time_frame>RW Period Baseline, RW Period Week 24</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants 18 years and older with a non-missing value at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept, Before Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Rilonacept, Including Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
          <group group_id="O3">
            <title>Randomized Withdrawal Period: Placebo, Before Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
          <group group_id="O4">
            <title>Randomized Withdrawal Period: Placebo, Including Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From RW Period Baseline in the Short Form Health Survey-6 Domains (SF-6D) Utility Index Score at RW Period Week 24</title>
          <description>The SF-6D is calculated based on responses to 11 items on the SF-36, that correspond to 6 domains: physical functioning, role participation (combined role-physical and role-emotional), social functioning, bodily pain, mental health, and vitality. Individual respondents can be classified on any of 4 to 6 levels of functioning or limitations for each of 6 domains, thus allowing a respondent to be classified into any of 18,000 possible unique health states. Using a standard gamble technique, each of these health states were mapped onto the SF-6D index score, which ranges from 0.00 (worst possible health state/death) to 1.00 (best possible health state/perfect health).</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants 18 years and older with a non-missing value at given time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0385" spread="0.10879"/>
                    <measurement group_id="O2" value="0.0385" spread="0.10879"/>
                    <measurement group_id="O3" value="-0.0027" spread="0.05705"/>
                    <measurement group_id="O4" value="-0.0005" spread="0.09871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From RW Period Baseline in 5-level EuroQoL-5 Dimensions (EQ-5D-5L) Individual Scores and Index Value to RW Period Week 24</title>
        <description>The EQ-5D-5L is a self-reported health status questionnaire that consists of 6 questions used to calculate a health utility score for use in health economic analysis. There are 2 components to the EQ-5D-5L: a 5-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Individual and index scores range from 0 to 1, with low scores representing a higher level of dysfunction. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.</description>
        <time_frame>RW Period Baseline, RW Period Week 24</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants 18 years and older with a non-missing value at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept, Before Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Rilonacept, Including Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
          <group group_id="O3">
            <title>Randomized Withdrawal Period: Placebo, Before Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
          <group group_id="O4">
            <title>Randomized Withdrawal Period: Placebo, Including Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From RW Period Baseline in 5-level EuroQoL-5 Dimensions (EQ-5D-5L) Individual Scores and Index Value to RW Period Week 24</title>
          <description>The EQ-5D-5L is a self-reported health status questionnaire that consists of 6 questions used to calculate a health utility score for use in health economic analysis. There are 2 components to the EQ-5D-5L: a 5-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Individual and index scores range from 0 to 1, with low scores representing a higher level of dysfunction. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants 18 years and older with a non-missing value at given time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at RW Week 24 in Mobility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.52"/>
                    <measurement group_id="O2" value="-0.1" spread="0.52"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="-0.1" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 24 in Self-Care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.26"/>
                    <measurement group_id="O2" value="-0.1" spread="0.26"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.1" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 24 in Usual Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.70"/>
                    <measurement group_id="O2" value="-0.1" spread="0.70"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.1" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 24 in Pain/Discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.92"/>
                    <measurement group_id="O2" value="0.1" spread="0.92"/>
                    <measurement group_id="O3" value="0.0" spread="1.00"/>
                    <measurement group_id="O4" value="0.1" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 24 in Anxiety/Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.83"/>
                    <measurement group_id="O2" value="-0.1" spread="0.83"/>
                    <measurement group_id="O3" value="-0.3" spread="0.58"/>
                    <measurement group_id="O4" value="0.0" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 24 in Index Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0033" spread="0.09812"/>
                    <measurement group_id="O2" value="0.0033" spread="0.09812"/>
                    <measurement group_id="O3" value="0.0413" spread="0.15635"/>
                    <measurement group_id="O4" value="0.0029" spread="0.08592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RW Week 24 in VAS Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="17.32"/>
                    <measurement group_id="O2" value="7.5" spread="17.32"/>
                    <measurement group_id="O3" value="10.0" spread="10.15"/>
                    <measurement group_id="O4" value="-8.3" spread="29.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From RW Period Baseline in Insomnia Severity Index (ISI) Total Score at RW Period Week 24</title>
        <description>Participant's sleep quality was assessed with the ISI survey questionnaire. The ISI is a 7-item survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. Scores are summed for a total score, which ranges from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia.&#xD;
Clinical interpretation of the total score is as follows:&#xD;
0 to 7 = no clinically significant insomnia; 8 to 14 = subthreshold insomnia; 15 to 21 = clinical insomnia (moderate severity); 22 to 28 = clinical insomnia (severe).</description>
        <time_frame>RW Period Baseline, RW Period Week 24</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants 18 years and older with a non-missing value at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept, Before Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Rilonacept, Including Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
          <group group_id="O3">
            <title>Randomized Withdrawal Period: Placebo, Before Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
          <group group_id="O4">
            <title>Randomized Withdrawal Period: Placebo, Including Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From RW Period Baseline in Insomnia Severity Index (ISI) Total Score at RW Period Week 24</title>
          <description>Participant's sleep quality was assessed with the ISI survey questionnaire. The ISI is a 7-item survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. Scores are summed for a total score, which ranges from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia.&#xD;
Clinical interpretation of the total score is as follows:&#xD;
0 to 7 = no clinically significant insomnia; 8 to 14 = subthreshold insomnia; 15 to 21 = clinical insomnia (moderate severity); 22 to 28 = clinical insomnia (severe).</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period. Participants 18 years and older with a non-missing value at given time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="4.75"/>
                    <measurement group_id="O2" value="-0.7" spread="4.75"/>
                    <measurement group_id="O3" value="-0.3" spread="3.79"/>
                    <measurement group_id="O4" value="-0.2" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ISI Categories From RW Period Baseline to RW Period Week 24</title>
        <description>Participant's sleep quality was assessed with the ISI survey questionnaire. The ISI is a 7-item survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. Scores are summed for a total score, which ranges from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia.&#xD;
Clinical interpretation of the total score is as follows:&#xD;
0 to 7 = no clinically significant insomnia; 8 to 14 = subthreshold insomnia; 15 to 21 = clinical insomnia (moderate severity); 22 to 28 = clinical insomnia (severe).</description>
        <time_frame>RW Period Baseline (BL), RW Period Week (Wk) 24</time_frame>
        <population>ITT Week 24 Analysis Set: All participants randomized at least 24 weeks before data cutoff. Participants 18 years or older</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept, Before Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Rilonacept, Including Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
          <group group_id="O3">
            <title>Randomized Withdrawal Period: Placebo, Before Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
          <group group_id="O4">
            <title>Randomized Withdrawal Period: Placebo, Including Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ISI Categories From RW Period Baseline to RW Period Week 24</title>
          <description>Participant's sleep quality was assessed with the ISI survey questionnaire. The ISI is a 7-item survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. Scores are summed for a total score, which ranges from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia.&#xD;
Clinical interpretation of the total score is as follows:&#xD;
0 to 7 = no clinically significant insomnia; 8 to 14 = subthreshold insomnia; 15 to 21 = clinical insomnia (moderate severity); 22 to 28 = clinical insomnia (severe).</description>
          <population>ITT Week 24 Analysis Set: All participants randomized at least 24 weeks before data cutoff. Participants 18 years or older</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL No Clinically Significant Insomnia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Wk 24 No Clinically Significant Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 24 Subthreshold Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 24 Clinical Insomnia, Moderate Severity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 24 Clinical Insomnia, Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 24 Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL Subthreshold Insomnia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Wk 24 No Clinically Significant Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 24 Subthreshold Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 24 Clinical Insomnia, Moderate Severity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 24 Clinical Insomnia, Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 24 Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL Clinical Insomnia, Moderate Severity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Wk 24 No Clinically Significant Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 24 Subthreshold Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 24 Clinical Insomnia, Moderate Severity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 24 Clinical Insomnia, Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 24 Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL Clinical Insomnia, Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Wk 24 No Clinically Significant Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 24 Subthreshold Insomnia</title>
                </category>
                <category>
                  <title>Wk 24 Clinical Insomnia, Moderate Severity</title>
                </category>
                <category>
                  <title>Wk 24 Clinical Insomnia, Severe</title>
                </category>
                <category>
                  <title>Wk 24 Missing</title>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL Missing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Wk 24 No Clinically Significant Insomnia</title>
                </category>
                <category>
                  <title>Wk 24 Subthreshold Insomnia</title>
                </category>
                <category>
                  <title>Wk 24 Clinical Insomnia, Moderate Severity</title>
                </category>
                <category>
                  <title>Wk 24 Clinical Insomnia, Severe</title>
                </category>
                <category>
                  <title>Wk 24 Missing</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Using Oral Rescue Therapy (ORT), Corticosteroid, or Bailout Rilonacept for Pericarditis Every 4 Weeks Cumulatively in the RW Period</title>
        <description>ORT included analgesics, NSAIDs, and/or colchicine. ORT use while waiting for at least 5 days since previous administration of study drug before receiving bailout, or within 5 days before the assessment of pericarditis recurrence, was excluded.</description>
        <time_frame>RW Period (mean 24.8 weeks)</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Using Oral Rescue Therapy (ORT), Corticosteroid, or Bailout Rilonacept for Pericarditis Every 4 Weeks Cumulatively in the RW Period</title>
          <description>ORT included analgesics, NSAIDs, and/or colchicine. ORT use while waiting for at least 5 days since previous administration of study drug before receiving bailout, or within 5 days before the assessment of pericarditis recurrence, was excluded.</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ORT : First Use ≤ 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ORT : First Use ≤ 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ORT : First Use ≤ 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ORT : First Use ≤ 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ORT : First Use ≤ 20 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ORT : First Use ≤ 24 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ORT : All Weeks (Including &gt; 24 Weeks in RW Period)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corticosteroid : First Use ≤ 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corticosteroid : First Use ≤ 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corticosteroid : First Use ≤ 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corticosteroid : First Use ≤ 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corticosteroid : First Use ≤ 20 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corticosteroid : First Use ≤ 24 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corticosteroid : All Weeks (Including &gt; 24 Weeks in RW Period)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bailout : First Use ≤ 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bailout : First Use ≤ 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bailout : First Use ≤ 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="61.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bailout : First Use ≤ 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="67.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bailout : First Use ≤ 20 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bailout : First Use ≤ 24 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bailout : All Weeks (Including &gt; 24 Weeks in RW Period)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total (any of the above) : First Use ≤ 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total (any of the above) : First Use ≤ 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total (any of the above) : First Use ≤ 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="64.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total (any of the above) : First Use ≤ 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total (any of the above) : First Use ≤ 20 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total (any of the above) : First Use ≤ 24 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total (any of the above) : All Weeks (Including &gt; 24 Weeks in RW Period)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="77.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Participants who used ORT, corticosteroids or bailout rilonacept during the RW Period</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Two-sided p value calculated using a Cochran-Mantel-Haenszel test adjudicated by randomization strata.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.015</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.108</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Using ORT for Pericarditis in the First 24 Weeks of RW Period</title>
        <description>ORT included analgesics, NSAIDs, and/or colchicine.</description>
        <time_frame>RW Period (up to Week 24)</time_frame>
        <population>ITT Analysis Set: all participants who were randomized in the RW period.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Using ORT for Pericarditis in the First 24 Weeks of RW Period</title>
          <description>ORT included analgesics, NSAIDs, and/or colchicine.</description>
          <population>ITT Analysis Set: all participants who were randomized in the RW period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pericardial Delayed Hyperenhancement, Myocardial Delayed Hyperenhancement or Pericardial Effusion on Magnetic Resonance Imaging (MRI) at RW Week 24</title>
        <description>MRI assessments were performed in a subgroup of participants (MRI substudy) to assess the percentage of participants with:&#xD;
Pericardial delayed hyperenhancement&#xD;
Myocardial delayed hyperenhancement&#xD;
Pericardial effusion</description>
        <time_frame>RW Period Week 24</time_frame>
        <population>ITT Week 24 Analysis Set: All participants randomized at least 24 weeks before data cutoff. Participants in the MRI substudy with nonmissing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Withdrawal Period: Rilonacept, Before Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Withdrawal Period: Rilonacept, Including Bailout Rilonacept</title>
            <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
          <group group_id="O3">
            <title>Randomized Withdrawal Period: Placebo</title>
            <description>Double-blind placebo SC injections once weekly.</description>
          </group>
          <group group_id="O4">
            <title>Randomized Withdrawal Period: Placebo, Including Bailout Rilonacept</title>
            <description>Double-blind placebo SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pericardial Delayed Hyperenhancement, Myocardial Delayed Hyperenhancement or Pericardial Effusion on Magnetic Resonance Imaging (MRI) at RW Week 24</title>
          <description>MRI assessments were performed in a subgroup of participants (MRI substudy) to assess the percentage of participants with:&#xD;
Pericardial delayed hyperenhancement&#xD;
Myocardial delayed hyperenhancement&#xD;
Pericardial effusion</description>
          <population>ITT Week 24 Analysis Set: All participants randomized at least 24 weeks before data cutoff. Participants in the MRI substudy with nonmissing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pericardial Delayed Hyperenhancement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial Delayed Hyperenhancement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pericardial Effusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From First Dose to Pain Response in the RI Period</title>
        <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Time to pain response was defined as number of days from first dose to the first day a participant's daily pain NRS was ≤ 2 of the 3 days over which the rolling average daily pain NRS was ≤ 2.</description>
        <time_frame>RI Period (up to 12 weeks)</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with a baseline NRS measurement &gt;= 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From First Dose to Pain Response in the RI Period</title>
          <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Time to pain response was defined as number of days from first dose to the first day a participant's daily pain NRS was ≤ 2 of the 3 days over which the rolling average daily pain NRS was ≤ 2.</description>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with a baseline NRS measurement &gt;= 3.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="4.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From First Dose to CRP Normalization in the RI Period</title>
        <description>Time to CRP normalization, defined as CRP ≤ 0.5 mg/dL, was censored at treatment discontinuation, taking prohibited medication, or Week 12, whichever occurred first.</description>
        <time_frame>RI Period (up to 12 weeks)</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with a baseline CRP measurement &gt;= 0.5 mg/dL.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From First Dose to CRP Normalization in the RI Period</title>
          <description>Time to CRP normalization, defined as CRP ≤ 0.5 mg/dL, was censored at treatment discontinuation, taking prohibited medication, or Week 12, whichever occurred first.</description>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with a baseline CRP measurement &gt;= 0.5 mg/dL.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="5.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From First Dose to Rilonacept Monotherapy in RI Period</title>
        <description>Time to rilonacept monotherapy was defined as the number of weeks from first dose to the first day of achieving monotherapy.</description>
        <time_frame>RI Period (up to 12 weeks)</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with background therapies at RI Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From First Dose to Rilonacept Monotherapy in RI Period</title>
          <description>Time to rilonacept monotherapy was defined as the number of weeks from first dose to the first day of achieving monotherapy.</description>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with background therapies at RI Baseline.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="7.0" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From First Dose to Treatment Response in RI Period</title>
        <description>Time to treatment response is defined as time from first dose to the first day of pain response, and CRP ≤ 0.5 mg/dL within 7 days before or after pain response. Treatment response day will be the first day that the above criterion is met. If pain response occurs before CRP ≤ 0.5 mg/dL, each 3-day rolling average of NRS should be ≤ 2.0 from the day of pain response to the day of CRP ≤ 0.5 mg/dL. The response day will be the day of pain response. If CRP ≤0.5 mg/dL occurs before pain response, the response day will also be the day of pain response.</description>
        <time_frame>RI Period (up to 12 weeks)</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with baseline measurements of CRP &gt;0.5 mg/dL and NRS &gt; 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From First Dose to Treatment Response in RI Period</title>
          <description>Time to treatment response is defined as time from first dose to the first day of pain response, and CRP ≤ 0.5 mg/dL within 7 days before or after pain response. Treatment response day will be the first day that the above criterion is met. If pain response occurs before CRP ≤ 0.5 mg/dL, each 3-day rolling average of NRS should be ≤ 2.0 from the day of pain response to the day of CRP ≤ 0.5 mg/dL. The response day will be the day of pain response. If CRP ≤0.5 mg/dL occurs before pain response, the response day will also be the day of pain response.</description>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with baseline measurements of CRP &gt;0.5 mg/dL and NRS &gt; 2.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="4.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Clinical Response at RI Period Week 12</title>
        <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Clinical Response was defined as a weekly average of daily pericarditis pain of ≤ 2.0 on the 11-point NRS and CRP level ≤ 0.5 mg/dL and participants must have been able to stop background SOC pericarditis therapy by Week 10.</description>
        <time_frame>RI Period Week 12</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants achieving treatment response in the RI period.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Clinical Response at RI Period Week 12</title>
          <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. Clinical Response was defined as a weekly average of daily pericarditis pain of ≤ 2.0 on the 11-point NRS and CRP level ≤ 0.5 mg/dL and participants must have been able to stop background SOC pericarditis therapy by Week 10.</description>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants achieving treatment response in the RI period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Achieved Clinical Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Achieve Clinical Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CRP Normalization at RI Period Week 12</title>
        <description>CRP normalization was defined as CRP ≤ 0.5 mg/dL.</description>
        <time_frame>RI Period Week 12</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with a baseline CRP measurement ≥ 0.5 mg/dL.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CRP Normalization at RI Period Week 12</title>
          <description>CRP normalization was defined as CRP ≤ 0.5 mg/dL.</description>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with a baseline CRP measurement ≥ 0.5 mg/dL.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Over Time in Weekly Average of Pericarditis Pain NRS Score in RI Period</title>
        <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'.</description>
        <time_frame>RI Period Baseline, RI Period Weeks 1-12</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with an assessment at given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Over Time in Weekly Average of Pericarditis Pain NRS Score in RI Period</title>
          <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point numerical rating scale (NRS), where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'.</description>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with an assessment at given time period.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RI Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" spread="2.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.31" spread="2.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.18" spread="2.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.28" spread="2.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.51" spread="2.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.55" spread="2.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.70" spread="2.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.81" spread="2.663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.92" spread="2.569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.81" spread="2.727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.83" spread="2.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.05" spread="2.596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.01" spread="2.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Over Time in CRP Levels in RI Period</title>
        <time_frame>RI Period Baseline, RI Period Day 4, Weeks 1, 2, 4, 6, 12</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with an assessment at given time period.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Over Time in CRP Levels in RI Period</title>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with an assessment at given time period.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RI Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" spread="5.719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.80" spread="4.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.48" spread="5.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.55" spread="5.717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.46" spread="5.809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.55" spread="5.899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at RI Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.60" spread="5.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Resolution of Pericarditis-Related ECHO and ECG Abnormalities at Week 12 of the RI Period</title>
        <time_frame>RI Period Baseline, RI Period Week 12</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with ECHO and ECG abnormalities at RI Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period: ECHO Abnormality at Baseline</title>
            <description>Participants with an ECHO abnormality (ST-Elevation) at RI period baseline.</description>
          </group>
          <group group_id="O2">
            <title>Run-in Period: ECG Abnormality (ST-Elevation) at Baseline</title>
            <description>Participants with an ECG abnormality (ST-elevation) at RI period baseline.</description>
          </group>
          <group group_id="O3">
            <title>Run-in Period: ECG Abnormality (PR Depression) at Baseline</title>
            <description>Participants with an ECG abnormality (PR depression) at RI period baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Resolution of Pericarditis-Related ECHO and ECG Abnormalities at Week 12 of the RI Period</title>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with ECHO and ECG abnormalities at RI Baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With No or Minimal Pain in the RI Period While on Treatment</title>
        <description>No or minimal pain is defined as non-missing daily NRS ≤ 2, where participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point NRS, where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'.</description>
        <time_frame>RI Period (up to Week 12)</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With No or Minimal Pain in the RI Period While on Treatment</title>
          <description>No or minimal pain is defined as non-missing daily NRS ≤ 2, where participants were asked to select the score that best describes their average level of pericarditis pain over the previous 24 hours using an 11-point NRS, where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'.</description>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.54" spread="21.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With No or Minimal Pericarditis Symptoms Over Time in the RI Period, Based on the PGIPS</title>
        <description>The PGIPS, a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered using a 7-point rating scale ranging from absent (0=no recurrent pericarditis symptoms) to very severe (6=recurrent pericarditis symptoms cannot be ignored and markedly limits daily activities).&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
        <time_frame>RI Period Baseline, RI Period Weeks 6 and 12</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with an assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With No or Minimal Pericarditis Symptoms Over Time in the RI Period, Based on the PGIPS</title>
          <description>The PGIPS, a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered using a 7-point rating scale ranging from absent (0=no recurrent pericarditis symptoms) to very severe (6=recurrent pericarditis symptoms cannot be ignored and markedly limits daily activities).&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with an assessment at given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="10.48" upper_limit="28.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" lower_limit="80.31" upper_limit="95.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6" lower_limit="84.57" upper_limit="97.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With No or Minimal Pericarditis Activity Over Time in the RI Period, Based on the PGA-PA</title>
        <description>The PGA-PA is a single-item, clinician-reported outcome measure that Investigators use to rate their impression of the patient's overall pericarditis disease activity at the time the assessment is completed, using a rating scale ranging from absent to very severe. The Investigator selected the box that best described a participant's pericarditis activity at the time of occurrence of the assessment: Absent, Minimal, Mild, Moderate, Moderately Severe, Severe, Very Severe.&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
        <time_frame>RI Period Baseline, RI Period Weeks 6 and 12</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with an assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With No or Minimal Pericarditis Activity Over Time in the RI Period, Based on the PGA-PA</title>
          <description>The PGA-PA is a single-item, clinician-reported outcome measure that Investigators use to rate their impression of the patient's overall pericarditis disease activity at the time the assessment is completed, using a rating scale ranging from absent to very severe. The Investigator selected the box that best described a participant's pericarditis activity at the time of occurrence of the assessment: Absent, Minimal, Mild, Moderate, Moderately Severe, Severe, Very Severe.&#xD;
The exact 95% CI is calculated with randomization strata pooled. Participants who had received bailout rilonacept or rescue medication before the time point were considered nonresponders.</description>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with an assessment at given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RI Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="4.96" upper_limit="19.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RI Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8" lower_limit="87.23" upper_limit="98.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RI Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="93.23" upper_limit="99.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From RI Period Baseline in the SF-36 Domain Scores and Physical and Mental Scores to RI Period Week 12</title>
        <description>The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scores on each item are summed and averaged (range: 0=worst to 100=best) with higher scores indicating better health. Increases from baseline indicate improvement.</description>
        <time_frame>RI Period Baseline, RI Period Week 12</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with an assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From RI Period Baseline in the SF-36 Domain Scores and Physical and Mental Scores to RI Period Week 12</title>
          <description>The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scores on each item are summed and averaged (range: 0=worst to 100=best) with higher scores indicating better health. Increases from baseline indicate improvement.</description>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with an assessment at given time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Component Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Emotional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From RI Period Baseline in SF-6D Scores at RI Period Week 12</title>
        <description>The SF-6D is calculated based on responses to 11 items on the SF-36, that correspond to 6 domains: physical functioning, role participation (combined role-physical and role-emotional), social functioning, bodily pain, mental health, and vitality. Individual respondents can be classified on any of 4 to 6 levels of functioning or limitations for each of 6 domains, thus allowing a respondent to be classified into any of 18,000 possible unique health states. Using a standard gamble technique, each of these health states were mapped onto the SF-6D index score, which ranges from 0.00 (worst possible health state/death) to 1.00 (best possible health state/perfect health).</description>
        <time_frame>RI Period Baseline, RI Period Week 12</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with an assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From RI Period Baseline in SF-6D Scores at RI Period Week 12</title>
          <description>The SF-6D is calculated based on responses to 11 items on the SF-36, that correspond to 6 domains: physical functioning, role participation (combined role-physical and role-emotional), social functioning, bodily pain, mental health, and vitality. Individual respondents can be classified on any of 4 to 6 levels of functioning or limitations for each of 6 domains, thus allowing a respondent to be classified into any of 18,000 possible unique health states. Using a standard gamble technique, each of these health states were mapped onto the SF-6D index score, which ranges from 0.00 (worst possible health state/death) to 1.00 (best possible health state/perfect health).</description>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with an assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1828" spread="0.12658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From RI Period Baseline in 5-level EuroQoL-5 Dimensions (EQ-5D-5L) Individual Scores and Index Value at RI Period Week 12</title>
        <description>The EQ-5D-5L is a self-reported health status questionnaire that consists of 6 questions used to calculate a health utility score for use in health economic analysis. There are 2 components to the EQ-5D-5L: a 5-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Individual and index scores range from 0 to 1, with low scores representing a higher level of dysfunction. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.</description>
        <time_frame>RI Period Baseline, RI Period Week 12</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with an assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From RI Period Baseline in 5-level EuroQoL-5 Dimensions (EQ-5D-5L) Individual Scores and Index Value at RI Period Week 12</title>
          <description>The EQ-5D-5L is a self-reported health status questionnaire that consists of 6 questions used to calculate a health utility score for use in health economic analysis. There are 2 components to the EQ-5D-5L: a 5-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Individual and index scores range from 0 to 1, with low scores representing a higher level of dysfunction. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.</description>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with an assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mobility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-Care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/Discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Index Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1626" spread="0.16814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" spread="23.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From RI Period Baseline in ISI Total Score at RI Period Week 12</title>
        <description>Participant's sleep quality was assessed with the ISI survey questionnaire. The ISI is a 7-item survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. Scores are summed for a total score, which ranges from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia.&#xD;
Clinical interpretation of the total score is as follows:&#xD;
0 to 7 = no clinically significant insomnia; 8 to 14 = subthreshold insomnia; 15 to 21 = clinical insomnia (moderate severity); 22 to 28 = clinical insomnia (severe).</description>
        <time_frame>RI Period Baseline, RI Period Week 12</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with an assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From RI Period Baseline in ISI Total Score at RI Period Week 12</title>
          <description>Participant's sleep quality was assessed with the ISI survey questionnaire. The ISI is a 7-item survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. Scores are summed for a total score, which ranges from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia.&#xD;
Clinical interpretation of the total score is as follows:&#xD;
0 to 7 = no clinically significant insomnia; 8 to 14 = subthreshold insomnia; 15 to 21 = clinical insomnia (moderate severity); 22 to 28 = clinical insomnia (severe).</description>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants with an assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ISI Categories From RI Period Baseline to RI Period Week 12</title>
        <description>Participant's sleep quality was assessed with the ISI survey questionnaire. The ISI is a 7-item survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. Scores are summed for a total score, which ranges from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia.&#xD;
Clinical interpretation of the total score is as follows:&#xD;
0 to 7 = no clinically significant insomnia; 8 to 14 = subthreshold insomnia; 15 to 21 = clinical insomnia (moderate severity); 22 to 28 = clinical insomnia (severe).</description>
        <time_frame>RI Period Baseline (BL), RI Period Week (Wk) 12</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants 18 years or older with an assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ISI Categories From RI Period Baseline to RI Period Week 12</title>
          <description>Participant's sleep quality was assessed with the ISI survey questionnaire. The ISI is a 7-item survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. Scores are summed for a total score, which ranges from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia.&#xD;
Clinical interpretation of the total score is as follows:&#xD;
0 to 7 = no clinically significant insomnia; 8 to 14 = subthreshold insomnia; 15 to 21 = clinical insomnia (moderate severity); 22 to 28 = clinical insomnia (severe).</description>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants 18 years or older with an assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL No Clinically Significant Insomnia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Wk 12 No Clinically Significant Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Subthreshold Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Clinical Insomnia, Moderate Severity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Clinical Insomnia, Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL Subthreshold Insomnia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Wk 12 No Clinically Significant Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Subthreshold Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Clinical Insomnia, Moderate Severity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Clinical Insomnia, Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL Clinical Insomnia, Moderate Severity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Wk 12 No Clinically Significant Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Subthreshold Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Clinical Insomnia, Moderate Severity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Clinical Insomnia, Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL Clinical Insomnia, Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Wk 12 No Clinically Significant Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Subthreshold Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Clinical Insomnia, Moderate Severity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Clinical Insomnia, Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL Missing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Wk 12 No Clinically Significant Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Subthreshold Insomnia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Clinical Insomnia, Moderate Severity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Clinical Insomnia, Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Wk 12 Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Were Off Background Pericarditis Medication on or Before RI Period Weeks 4, 8, 10, and 12</title>
        <time_frame>RI Period Baseline, RI Period Weeks 4, 8, 10, 12</time_frame>
        <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants 18 years or older with an assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Off Background Pericarditis Medication on or Before RI Period Weeks 4, 8, 10, and 12</title>
          <population>Run-in Analysis Set: All participants who received at least 1 dose of study drug in the RI period. Participants 18 years or older with an assessment at given time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RI Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Not Receiving Background Pericarditis Medication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Receiving Background Pericarditis Medication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RI Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Not Receiving Background Pericarditis Medication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Receiving Background Pericarditis Medication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RI Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Not Receiving Background Pericarditis Medication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Receiving Background Pericarditis Medication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RI Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Not Receiving Background Pericarditis Medication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Receiving Background Pericarditis Medication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RI Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Not Receiving Background Pericarditis Medication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Receiving Background Pericarditis Medication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Pericarditis Recurrences (Based on Investigators' Judgement) in the Long-Term Extension (LTE) Period</title>
        <description>Pericarditis recurrence is defined as the recurrence of typical pericarditis pain associated with supportive objective evidence of pericarditis. At any time during the RW period, participants who experienced a suspected recurrence of pericarditis symptoms reported to the study site/clinic for a scheduled or unscheduled visit, during which clinical assessments were performed to gather all the necessary diagnostic data to confirm or rule out the presence of pericarditis recurrence.</description>
        <time_frame>LTE Period (up to 24 months)</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response at Each CRP Assessment (Weeks 12 and 24) of the LTE Period</title>
        <description>Clinical response is defined as rilonacept monotherapy + CRP ≤ 0.5 mg/dL + NRS ≤ 2. Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point NRS, where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'. The pain NRS at the visit when CRP was assessed was used.</description>
        <time_frame>LTE Period Weeks 12 and 24</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From LTE Baseline Over Time in CRP Levels</title>
        <time_frame>LTE Baseline, up to 24 months</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From LTE Baseline Over Time in Pericarditis Pain NRS</title>
        <description>Participants were asked to select the score that best described their average level of pericarditis pain over the previous 24 hours using an 11-point NRS, where zero (0) indicates 'no pain' and ten (10) indicates 'pain as bad as it could be'.</description>
        <time_frame>LTE Baseline, up to 24 months</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Absent or Minimal Pericarditis Activity In the LTE Period Based on the PGIPS</title>
        <description>Percentage of participants with no or minimal pericarditis symptoms in the LTE Period, based on the PGIPS, a single-item measure of the participant's impression of the overall severity of pericarditis symptoms at the time the questionnaire is administered using a 7-point rating scale ranging from absent (0=no recurrent pericarditis symptoms) to very severe (6=recurrent pericarditis symptoms that cannot be ignored and markedly limits daily activities).</description>
        <time_frame>LTE Period (up to 24 months)</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Absent or Minimal Pericarditis Activity Over Time in the LTE Period Based on the PGA-PA</title>
        <description>The PGA-PA is a single-item, clinician-reported outcome measure that Investigators use to rate their impression of the patient's overall pericarditis disease activity at the time the assessment is completed, using a rating scale ranging from absent to very severe. The Investigator selected the box that best described a participant's pericarditis activity at the time of occurrence of the assessment: Absent, Minimal, Mild, Moderate, Moderately Severe, Severe, Very Severe.</description>
        <time_frame>LTE Period (up to 24 months)</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From RI Baseline in the SF-36 Domain Scores and Physical and Mental Scores in the LTE Period</title>
        <description>The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scores on each item are summed and averaged (range: 0=worst to 100=best) with higher scores indicating better health. Increases from baseline indicate improvement.</description>
        <time_frame>LTE Baseline, up to 24 months</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From LTE Baseline in SF-6D Scores in LTE Period</title>
        <description>The SF-6D is calculated based on responses to 11 items on the SF-36, that correspond to 6 domains: physical functioning, role participation (combined role-physical and role-emotional), social functioning, bodily pain, mental health, and vitality. Individual respondents can be classified on any of 4 to 6 levels of functioning or limitations for each of six domains, thus allowing a respondent to be classified into any of 18,000 possible unique health states. Using a standard gamble technique, each of these health states were mapped onto the SF-6D index score, which ranges from 0.00 (worst possible health state/death) to 1.00 (best possible health state/perfect health).</description>
        <time_frame>LTE Baseline, up to 24 months</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From LTE Baseline in EQ-5D-5L Individual Scores and Index Value in the LTE Period</title>
        <description>The EQ-5D-5L is a self-reported health status questionnaire that consists of 6 questions used to calculate a health utility score for use in health economic analysis. There are 2 components to the EQ-5D-5L: a 5-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Individual and index scores range from 0 to 1, with low scores representing a higher level of dysfunction. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.</description>
        <time_frame>LTE Baseline, up to 24 months</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From LTE Baseline in ISI Total Score in the LTE Period</title>
        <description>Participant's sleep quality was assessed with the ISI survey questionnaire. The ISI is a 7-item survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. Scores are summed for a total score, which ranges from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia.&#xD;
Clinical interpretation of the total score is as follows:&#xD;
0 to 7 = no clinically significant insomnia; 8 to 14 = subthreshold insomnia; 15 to 21 = clinical insomnia (moderate severity); 22 to 28 = clinical insomnia (severe).</description>
        <time_frame>LTE Baseline, up to 24 months</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From LTE Baseline in ISI Categories in the LTE Period</title>
        <description>Participant's sleep quality was assessed with the ISI survey questionnaire. The ISI is a 7-item survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. Scores are summed for a total score, which ranges from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia.&#xD;
Clinical interpretation of the total score is as follows:&#xD;
0 to 7 = no clinically significant insomnia; 8 to 14 = subthreshold insomnia; 15 to 21 = clinical insomnia (moderate severity); 22 to 28 = clinical insomnia (severe).</description>
        <time_frame>LTE Baseline, up to 24 months</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Addition of Standard of Care (SOC) Pericarditis Therapy Every 4 Weeks Cumulatively in the LTE Period</title>
        <time_frame>LTE Period (up to 24 months)</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From LTE Baseline in Pericardial Signs in ECHO in the LTE Period</title>
        <time_frame>LTE Baseline, up to 24 months</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From LTE Baseline in Pericardial Signs in ECG in LTE Period</title>
        <time_frame>LTE Baseline, up to 24 months</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From LTE Baseline in Pericardial Signs in MRI in the LTE Period</title>
        <time_frame>LTE Baseline, up to 24 months</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Corticosteroid Use Over Time in the LTE Period</title>
        <time_frame>LTE Period (up to 24 months)</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pericardial Delayed Hyperenhancement, Myocardial Delayed Hyperenhancement or Pericardial Effusion at LTE Period Week 24</title>
        <time_frame>LTE Period, Week 24</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Recurrent Rate</title>
        <description>Annualized recurrent rate was calculated for participants randomized to rilonacept utilizing pooled data in RW and LTE periods.&#xD;
Pericarditis recurrence was defined as the recurrence of typical pericarditis pain associated with supportive objective evidence of pericarditis. At any time during the RW period, participants who experienced a suspected recurrence of pericarditis symptoms reported to the study site/clinic for a scheduled or unscheduled visit, during which clinical assessments were performed to gather all the necessary diagnostic data to confirm or rule out the presence of pericarditis recurrence.</description>
        <time_frame>RW and LTE Periods</time_frame>
        <posting_date>05/2023</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>RI Period: from the first dose of study drug to the RW period randomization visit; mean treatment duration was 11.61 weeks. RW Period Rilonacept Only, Before Bailout: from RW period randomization to rilonacept until administration of bailout rilonacept; mean treatment duration was 24.40 weeks. RW Period Rilonacept, Including Bailout Rilonacept: from RW period randomization until administration of LTE rilonacept; mean treatment duration was 25.07 weeks.</time_frame>
      <desc>RW Period Placebo Only, Before Bailout: from RW period randomization to placebo until administration of bailout rilonacept; mean treatment duration was 9.88 weeks.&#xD;
RW Period Placebo, Including Bailout Rilonacept: from RW period randomization until administration of LTE rilonacept; mean treatment duration was 23.88 weeks.&#xD;
For participants who did not continue from the RI or RW period into LTE period, data on adverse events were collected for 6 weeks after last dose of rilonacept or placebo.</desc>
      <group_list>
        <group group_id="E1">
          <title>Run-in Period</title>
          <description>Single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) subcutaneous (SC), followed by 160 mg (or 2.2 mg/kg in pediatric subjects ≥12 and &lt;18 years old) injections once weekly for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Randomized Withdrawal Period: Rilonacept Only, Before Bailout Rilonacept</title>
          <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.</description>
        </group>
        <group group_id="E3">
          <title>Randomized Withdrawal Period: Rilonacept, Including Bailout Rilonacept</title>
          <description>Double-blind rilonacept 160 mg (or 2.2 mg/kg in pediatric participants ≥ 12 and &lt; 18 years old) SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
        </group>
        <group group_id="E4">
          <title>Randomized Withdrawal Period: Placebo Only, Before Bailout Rilonacept</title>
          <description>Double-blind placebo SC injections once weekly.</description>
        </group>
        <group group_id="E5">
          <title>Randomized Withdrawal Period: Placebo, Including Bailout Rilonacept</title>
          <description>Double-blind placebo SC injections once weekly.&#xD;
Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>High density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lipids increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has the first right to publish information obtained from the trial. After sponsor publishes, PI may publish its own trial results, provided that sponsor may embargo such publication for up to 60 days for purposes of identifying confidential information (other than trial data) that must be removed and up to an additional 120 days to prepare a patent application if there is patentable subject matter in the PI's proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Operations Study Director</name_or_title>
      <organization>Kiniksa Pharmaceuticals (UK), Ltd. c/o Kiniksa Pharmaceuticals Corp.</organization>
      <phone>1-781-431-9100</phone>
      <email>studyinfo@kiniksa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

